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Humans are afflicted by an enormous number of diseases with a genetic component, of which 
roughly 7,000 are thought to follow Mendelian inheritance. As these Mendelian diseases often 
have a large impact on normal development and quality of life, many studies are conducted 
using the affected individual’s genetic sequence in an effort to determine what has changed in 
which gene to cause them. If successful, this can then aid in understanding the disease and how 
best to manage it, as well as furthering the effort towards understanding the function of every 
gene in the human genome. Many techniques are used to locate the causative changes, or 
variants, that are causing a given Mendelian disease, such as using exome sequencing to search 
the coding regions of the genome, or comparative genomic hybridization to arrays (array-CGH) 
to identify large deletions or duplications.  
This analysis attempted to identify the genetic cause of unexplained disorders in two families, 
one affected with Otopalatodigital Syndrome Type 1 (OPD1) and the other affected with Larsen 
Syndrome. Both disorders are usually caused by variants in the genes that code for filamin 
proteins (FLNA and FLNB respectively). These families are atypical in that no causative variants 
in these genes had been found despite significant previous attempts. In the OPD1 family, the 
exons of the FLNA gene have previously been sequenced using the Sanger methodology and 
array-CGH had been performed, but no causal variant had been located. In the family affected 
by Larsen Syndrome, the Sanger methodology has been used to sequence across the exons and 




(MLPA) has been performed over the FLNB gene. Ultimately, the whole exome of this family trio 
was examined, but no causal variant had been identified. 
In this study, an analysis of whole genome sequence data was undertaken in an attempt to 
resolve the causation of the disorders in these two families. In the case of the family thought to 
be affected by OPD1, the child in fact had Rubinstein-Taybi syndrome; a disease with a similar 
phenotype but that is caused by mutations in the CREBBP gene, in this case a loss of a splice 
donor sequence at the beginning of exon 20. For the family affected by Larsen Syndrome 
multiple variants remain that could be causal, although none are particularly compelling. For 
this reason, it is not possible to definitively determine the cause of the disease and so no 
inferences about the genes with which FLNB interacts can be made. It is suggested that the 
analysis be repeated with further families as they become available, as the strength of the 
candidate genes would be greatly increased if they were also found in another family. Currently 
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1.1 Finding Human Disease Genes: A Rationale 
1.1.1 Genetics and disease 
Humans are affected by enormous numbers of diseases caused by many different things, such 
as pathogenic bacteria, lack of an essential nutrient from the environment, and errors in cellular 
control and function due to changes in an individual’s genetic code. While in some cases the 
cause of a disease is easily identified, in many cases it is extremely difficult. In particular, it can 
be incredibly hard to identify the gene or genes responsible for causing a genetic disease.  
Identifying the gene or genes that cause a disease can be difficult because while it is known that 
there is at least one genetic change, or causal variant, that has occurred to cause the disease 
there are also many changes in the genetic code of the average individual that don’t cause a 
disease, and the function of many genes is currently unknown. This makes identifying the cause 
of such genetic diseases hard because when there are changes, or variants, across many genes 
whose function is not well understood, it is impossible to say which of them is causing the 
disease. In addition to this, often a genetic disease is caused by variants in more than one gene 
which further compounds the issue, because to fully understand what is causing the disease it is 
necessary to understand the function of every gene involved and how they interact with one 
another. If it is possible to identify the exact genetic cause of a disease, there is the possibility of 
developing therapeutic interventions based on this knowledge, which if successful can lead to 




 Identifying candidate variants 
Because of these issues, many techniques have been developed to help to identify the 
variations in an individual’s genetic code that could be causing disease. Many tools, such as 
those in the Genome Analysis Toolkit (GATK), have been developed that can search an 
individual’s available DNA sequence and compare it to a standard reference sequence to find 
any changes and attempt to assess whether they are likely to affect the normal function of a 
gene or genes. These changes are known as candidate variants and are defined as any change 
within the genetic code from single nucleotide polymorphisms (SNPs) to variations in copy 
number to large chromosomal rearrangements, that could be causing the affected individual’s 
disease (Chong et al., 2015). However, when a disease is caused by variants in more than one 
gene it is often not possible to identify them, so most often molecular diagnosis is done when 
the disease follows Mendelian inheritance patterns, i.e. is caused by changes in a single gene.  
 Identifying gene function 
Once candidate variants have been identified along with the gene whose function they are 
predicted to affect, it is necessary to determine the function of that gene and how a change in 
its function could be causing the disease phenotype seen. In some cases, such as if the variant is 
in a gene known to cause a disease that presents with a phenotype like that of the individual in 
question, this is trivial. However, the majority of the time the candidate variant is in a gene 
whose function is completely or partially unknown, or the disease the gene is known to cause 
presents a phenotype that could not be confused with the phenotype seen in the patient. This 
necessitates further research to elucidate the relevant function of the gene in question. This can 




can confirm whether a candidate variant is causing the disease or not. However, when a disease 
is caused by changes in more than one gene, it is generally not possible to identify them all and 
understand how they contribute to the disease.  
1.1.2 Mendelian disease vs complex disease 
There are roughly 7,000 genetic diseases that follow Mendelian inheritance (i.e. are caused by 
changes in a single gene), although it is likely that there are more that are not yet defined 
(Boycott, Vanstone, Bulman, & MacKenzie, 2013). However, many diseases are due to changes 
in multiple genes in addition to environmental factors, such as cardiovascular disease (Feinleib 
et al., 1977). Diseases with a genetic basis that result from contributions from more than one 
gene, often with significant environmental contributions are called complex diseases. These can 
be difficult to study as the causative genes are often unknown, which makes it difficult to 
predict the phenotypic consequences of variants within them (Manolio et al., 2009). In addition 
to this, if multiple genes have a cumulative effect it is almost impossible to determine to what 
magnitude each gene is responsible for the disease (Alkuraya, 2016).  
In contrast, the causes of diseases that follow Mendelian inheritance are relatively easy to 
determine, as there is usually one variant in one gene causing the disease. Such a variant can 
sometimes be clearly identified as the cause of the disease, and finding it can provide a great 




1.1.3 The value of determining causal genes in Mendelian disease 
 Scientific value 
Often the gene that is disrupted in Mendelian diseases is of unknown function. As one of the 
main goals of genetics based biomedicine is to determine the function of every gene in the 
human genome (Saleheen et al., 2017), determining which gene has been disrupted by a variant 
to cause a disorder is valuable. This is because after finding a causative variant in a gene it is 
possible to further elucidate that gene’s function through the phenotype produced. For 
example, if the phenotype associated with a genetic disorder is that of decreased height, it can 
be surmised that the affected gene plays a role in the biological pathways that determine how 
tall someone is, either through playing a role in the production or regulation of growth hormone 
or through other means. 
Similarly, although the phenotypic effects of a genetic disease are obvious in many cases, the 
exact biological cause of these effects can remain unknown for a long time due to the lack of 
understanding of the pathways involved. Using genetic techniques to study such diseases can 
lead to increased understanding of these pathways, as once the gene is known its protein 
product can be determined. Following this, further study can be undertaken to work out what 
function that protein performs and with what it interacts. This in turn can lead to possible ways 





 Clinical value 
In addition to enhancing our understanding of the biology of inherited diseases and their 
associated pathways, using genetic techniques to determine exactly what variants are causing 
the disease can help diagnose the disorder (Bell, 2004). Once a causative variant for a disease 
has been found, such variants can be looked for in cases where the physician is concerned that 
an individual is susceptible to genetic disease, or when there is a detrimental phenotype but its 
cause is unknown. This is particularly useful in the case of older fathers, as paternal age plays a 
role in the likelihood of genetic disorders occurring in their offspring (Veltman & Brunner, 2012). 
In such cases, a genetic screen that looks for any variants in genes known to cause Mendelian 
disorders can be conducted, which can inform the prospective parents of what to expect and 
provide options for minimising the effect of the disease. 
Such diagnostic abilities are useful even when there is no adequate treatment, as is often the 
case with genetic diseases. This is because knowing what to expect and having management 
strategies available can reduce the burden of the disease for the affected individual and their 
family. In addition to this, having an accurate diagnosis often enables a more accurate prognosis, 
which can enable the best strategy of care to minimise harm. 
As well as aiding in the diagnosis and informing the prognosis of individuals with a Mendelian 
disease, determining the causal variant can help inform the affected individuals’ future 




Because of these positive outcomes from finding causal variants in affected individuals, a large 
amount of research is conducted with the aim of identifying them. There are many methods 
used to discover such genetic variants that cause disease, several of which are outlined below. 
1.2 Current methods of obtaining sequence to find causal variants 
1.2.1 Sequencing using the Sanger methodology 
One of the best-known and most widely used methods for obtaining genetic sequences is the 
Sanger methodology. Used as the standard method of obtaining sequence for nearly 40 years, 
sequencing using the Sanger methodology gives reliable and high-quality results down to a 
single base pair, and is therefore very useful for proving the existence of variants that could be 
causing disease. When sequencing according to the Sanger methodology, a reaction is 
performed to construct a DNA molecule where each base is known. Each reaction contains DNA 
polymerase and free oligonucleotides of all four standard bases, in addition to smaller 
quantities of the bases labelled in such a way that the incorporation of one of them halts 
extension of the molecule (SenGupta & Cookson, 2010). This means that as DNA polymerase 
constructs the strand of DNA it will stop at random points whenever it uses one of the labelled 
bases. Each labelled base fluoresces a distinct colour, so when separated by size and viewed, 
the sequence of the DNA strand is readable. This method is robust and reliable, but is limited to 





Although sequencing using the Sanger methodology gives very high-quality sequence data its 
usefulness for determining causal variants is limited. This is because it is very specific, as you 
need to design unique primers on either side of the section of DNA to be sequenced. Because of 
this specificity it is necessary to have candidate variants in mind before you design the 
sequencing polymerase chain reaction (PCR). It is also difficult and expensive to use the Sanger 
methodology to sequence all the coding regions of a candidate gene, as most genes are too long 
to be sequenced in a single reaction. This makes it necessary to sequence it in sections then 
search all the regions together, which can introduce errors (SenGupta & Cookson, 2010). 
The Sanger methodology is still widely used to prove that variants found in exome and whole 
genome data are not false positives, for example artefacts of the alignment process. However, it 
is not often used to look at long sequences of DNA or multiple genes. It is necessary to use 
another technique to find candidate variants, then confirm them by sequencing using the 
Sanger methodology. 
1.2.2 High throughput sequencing approaches 
Over the past decade innovative technologies have made the use of high throughput 
sequencing by the average researcher a possibility, as higher quality results have become 
available in tandem with decreased costs. This has made it much more plausible to obtain large 
quantities of sequence data to be used to determine candidate variants, including the entirety 
of the coding regions of an individual’s genome (the exome) and even the entire genome itself. 
This is particularly useful when a researcher is unsure of which gene is causing the phenotype 




competing techniques for producing this sequence, so here I will focus on the technology used 
by Illumina, as it is the most widely used and has been used in this study. 
 Illumina’s method 
First, the DNA to be investigated is fragmented into short pieces of a predetermined length 
(between 300 and 500 bases). The DNA used in this method can be up to the entire genomic 
sequence of an individual, but most often is the exome of an individual. 
To use this method to sequence an exome it is first necessary to “capture” (selectively 
sequence) the parts of the genome included. To accomplish this, the fragments of genomic DNA 
are hybridized in solution to a set of labelled synthetic oligonucleotides that covers all the 
regions of interest. Following this, the fragments of interest can be separated using the labels 
on the synthetic oligonucleotides. 
After fragmentation, adaptors are ligated onto both ends, along with a unique index sequence. 
These fragments are then loaded onto a flow cell, the surface of which has oligonucleotides 
complementary to the adaptors on the fragments. The fragments bind to the oligonucleotides, 
which are then amplified by bridge PCR to produce clusters that will provide sufficient signal for 
the rest of the analysis. Each flow cell has multiple lanes, each of which can produce millions of 
reads. This allows for the production of huge amounts of DNA in a short period of time. 
Following cluster formation, a primer is attached to the free end of the bound fragments, after 
which fluorescent nucleotides are added with polymerase. The nucleotides are blocked in such a 
way that only one can be incorporated at a time. A laser then excites the fluorescent molecule 




technique used in the Sanger methodology. After each cycle, the molecule blocking the addition 
of more nucleotides is removed so that another can be incorporated and the process repeats 
until the desired read length is reached. In the case of paired end reads, once the forward 
sequence has been determined the same is done for the reverse sequence. This process is called 
sequence-by-synthesis and is pictured in figure 1-1. 
 
Figure 1-1: A depiction of Illumina’s method for high throughput sequencing using sequence-by-synthesis. Adapted 
from http://www.3402bioinformaticsgroup.com/wp-content/uploads/2016/07/NGS.png, accessed 25/05/2017 
 
 Further processing 
After the fragments are sequenced they are separated in silico using the unique index 
sequences. The fragments are then aligned back to a reference sequence, producing DNA 
sequence for as much of the initially fragmented DNA as possible. Paired end reads can be used 




differences between this sequence and the reference sequence can then be used to identify 
candidate variants that could be causing the disease. 
After alignment, duplicated reads are removed as they can lead to incorrect conclusions about 
the biological signal of variants (Dozmorov et al., 2015). For example, if an error occurs in the 
initial extension of a fragment causing an apparent variant, and that fragment is duplicated 
many times, it can lead to a false conclusion that the individual in question has a variant at that 
position. Additionally, the confidence with which each base was identified during the 
sequencing stage is used to give them a quality score. The likelihood of these variants being real, 
or their quality, can then be measured using factors including the base quality scores. This list of 
variants can then be annotated with useful information, such as the frequency at which they are 
found in a control population (for example the Exome Aggregation Consortium, ExAC, which is a 
collection of the exomes of over 60,000 unrelated individuals) and their predicted effect on the 
protein produced by the gene they are in. These steps are usually performed using a workflow 
which contains tools to accomplish them, such as the Genome Analysis Toolkit (GATK). This 
approach is very useful for finding short variants, such as single nucleotide variants (SNVs) and 
small indels (the insertion or deletion of a small number of bases), most often in the exome of 
an individual. 
 Filtering the output of high throughput sequencing 
After annotation, the output of the workflow can be filtered using the results of the annotation 
to find variants that could be causal within the extensive list of variants produced. For example, 




off point. This is useful because if a variant is present at a relatively common frequency in a 
population of unaffected individuals then it is unlikely to be causing a rare and highly penetrant 
disease phenotype. Other useful ways of filtering are based on the predicted effect of a variant, 
as some types of variant are more likely to affect function than others, such as frameshift 
variants or a variant that destroys a splice site. Using these filters is necessary to reduce the 
number of candidate variants to a manageable number, as the number of variants in the 
average individual’s exome is huge, and there are more in the whole genome. 
 Trio design 
When filtering to find causal variants it is useful to use trio design. Trio design is using the 
sequence of the affected individual’s parents in addition to their own, as this enables the 
construction of inheritance models which means that particular types of variant can be filtered 
for. For example, using trio design you can construct a model that locates and retains variants 
present at positions where the affected child has a variant when compared to the reference 
sequence, but the parents do not, and removes everything else, i.e. de novo variants. Other 
models that can be used include recessive models for homozygous and compound heterozygous 
traits.  
 Exome data 
The exome is the subset of the genome contained within exons, i.e. the coding part of the 
genome, and most of the time will contain the disease-causing variant (Choi et al., 2009). 
Sequencing the whole exome of an individual has become routine, as evidenced by the 




contains the exomes of 60,706 individuals (URL http://exac.broadinstitute.org/). An exome 
sequence gives good coverage at very high resolution, down to individual bases. Utilising the 
filtering techniques outlined above with exome data gives a very good chance of finding the 
causative variant, but only if it is in a coding region of the genome. 
One disadvantage of using exome data is that there is no straightforward way to find structural 
variants in the data, as there is no simple way to filter for them. In addition to this, exome data 
has many false positives due to errors in annotation and alignment, so it is necessary to check 
the existence of any possible causative variants by sequencing using the Sanger methodology, 
which can be expensive if there are multiple candidate variants that remain after filtering. 
Another issue when using exome data is that the regions of the genome included vary 
depending on which capture platform you use, as different companies can include slightly 
different regions of the genome in their kits. As such it is possible that some variants could be 
missed during analysis. 
 Whole genome data 
Sometimes a researcher may choose to sequence the whole genome directly, although the cost 
is higher. Alternatively, if after examining exome data no variant likely to be causing the disease 
in the individual under investigation has been found, the entire genome may then be sequenced 
to obtain any candidate variants that may have been missed previously. Sequencing entire 
genomes using high throughput methods is expensive and analysing the data produced requires 




individual’s DNA down to base-pair resolution. This means that if there is a causative variant in 
the individual, it will likely be in the dataset. 
One problem with whole genome sequencing is that it is still possible to miss the causative 
variant even with the huge amount of data obtained. For example, it is often difficult to assess 
the significance of variants in non-coding regions because of the current general lack of 
knowledge about regulatory regions. In addition to this, whole genome data contains many 
false positive results because of misalignment or incorrect annotation (Steward et al., 2017). 
Because of this, it is necessary to validate the variants by sequencing using the Sanger 
methodology.  
1.2.1 Methods for finding structural variants 
 Array-CGH 
One of the main ways structural variants, especially deletions and duplications, can be found is 
by comparative genomic hybridization to arrays (CGH) (Carter, 2007). Using CGH arrays it is 
possible to perform a genome-wide analysis of copy number in one experiment. An array of 
overlapping target sequences, most often composed of known SNPs that are accurately mapped 
to the human genome, is developed through creating synthetic oligonucleotides, which are then 
attached to beads. These beads are then arrayed in wells across a slide. Following this, sample 
genomic DNA is added and allowed to hybridize to the array of sequences on the slide. The 
number of sample molecules hybridized is then counted and structural variants detected based 
on the number of hybridized molecules observed versus the number expected. This is relatively 




with long repeat sequences and cross-hybridization (Ylstra, van den Ijssel, Carvalho, Brakenhoff, 
& Meijer, 2006). In addition, the resolution of this technique is dependent on the map density of 
the markers used, which means that in order to ensure that no variants are missed by the 
analysis it is necessary to use huge numbers of markers. 
 MLPA 
Another way structural variants can be discovered in the human genome is by using MLPA 
(Multiplex Ligation-dependent Probe Amplification). MLPA is a method used to detect abnormal 
copy numbers across a small number (up to 40) of genomic DNA or RNA sequences (Schouten et 
al., 2002). In MLPA, probes added to the samples are amplified, rather than the sample nucleic 
acids themselves. Each probe consists of two oligonucleotides that hybridize to a target 
sequence next to each other, after which they can be ligated to each other. Ligated probes have 
identical sequences at their 5′ and 3′ ends, which means that all probes from a test can be 
amplified simultaneously in a PCR with only one pair of primers. 
MLPA is very sensitive, and can differentiate between sequences that differ in the deletion or 
duplication of only one copy of one exon, unlike most other techniques used to find variance in 
copy number. For example, Southern blots would find most deletions and duplications, but they 
take a lot of time and only find changes within the probes used, as well as requiring a large 
quantity of DNA (Schouten et al., 2002). In addition, heterozygous deletions and duplications in 
human DNA aren’t found through methods based on PCR amplification of genomic DNA, as a 
normal allele is also present in such samples. Other advantages of using MLPA are that it uses a 




(Schouten et al., 2002). The equipment necessary to perform MLPA is also widespread and 
present in many laboratories as standard. 
However, this technique is limited to using 40 target sequences per reaction, so it cannot be 
used unless you already have candidates with a high index of suspicion, similar to when using 
the Sanger methodology. Also, in order to perform MLPA you need to create the probes in the 
first place, which is time consuming, although once this is done generally enough probes are 
produced for a large number of reactions (Schouten et al., 2002). 
 Genomic data 
As genomic data contains sequence information for the entire genome, usually mapped using 
paired end reads, it can be used to find structural variants in addition to SNVs and indels. This is 
because if one of a pair of reads maps to a different location than the other half of the pair they 
will be flagged as discordant in the alignment data. Many discordant pairs of reads at the same 
position on the genome is suggestive of a structural variant. Another indication of the presence 
of a structural variant in genomic data is the average number of reads across an area. If the 
depth of coverage is significantly lower or higher than the average across the rest of the 
sequence data, it is possible that there is a structural variant at that location. Finally, during 
alignment a single read can be split to map to non-adjacent locations, which suggests that the 
read crosses the breakpoint of a structural variant in that individual. 
However, although it is possible to use these indicators to suggest a structural variant using 
genome data it is difficult to develop a way to filter for them with high confidence. This is 




map as discordant or split during alignment by mistake. In addition, there is a great deal of 
variability in the depth of coverage across the genome which can give a misleading impression 
that a deletion or insertion is causing decreased or increased coverage, when in fact it is due to 
chance. Because of these false positives, stringent filtering methods are required to use 
genomic data to search for structural variants as a consequence of which both the specificity 
and sensitivity of detecting true variants is reduced compared to the detection of SNVs and 
short indels. 
One method that can be used to identify structural variants from genomic sequence data is the 
GenomeStrIP SV workflow (Handsaker, Korn, Nemesh, & McCarroll, 2011). This workflow can 
only identify deletions, and it does so by using discordance between pairs of reads to suggest 
potential deletion breakpoints, after which it utilises depth of coverage to assess locations 
where a deletion may have occurred. Another workflow that attempts to characterise structural 
variants, in this case of all kinds, is Lumpy (Layer, Chiang, Quinlan, & Hall, 2014). Lumpy uses 
split reads and discordant reads in addition to the orientation of the paired reads to attempt to 
discover all structural variants. These methods of filtering the genomic data ultimately provide 
some candidate structural variants, although with a reduced sensitivity and specificity relative 




1.3  Families studied in this thesis and their conditions 
1.3.1 The families 
In this thesis, genomic sequences are utilised to attempt to determine the genetic cause of 
unexplained disorders in an affected child from two families, one affected with Otopalatodigital 
Syndrome Type 1 (OPD1) and the other affected with Larsen Syndrome. Both are disorders 
usually caused by variants in the genes that code for filamin proteins (FLNA and FLNB 
respectively). In this investigation, genomic data was used because in these families no 
causative variants have been found despite a thorough investigation. In the OPD1 family, all of 
the exons of the FLNA gene have previously been sequenced using the Sanger methodology and 
array-CGH has been performed. The Larsen syndrome family has previously been assessed using 
the Sanger methodology to sequence across the exons and exon/intron boundaries of the FLNB 
gene, as well as MLPA over the FLNB gene. Ultimately, the whole exome of this family trio was 
investigated, but still no causal variant was identified using standard filtering approaches. 
1.3.2 The Filamins and their genes 
 The filamin proteins and their structure 
The filamins are a family of actin binding proteins originally purified in 1974 by a group 
attempting to understand phagocytosis, who found that in their extracts there was actin, 
myosin and an unknown high molecular weight protein that bound to actin (Hartwig & Stossel, 
1975). In mammals, the Filamin family has three members, filamin A, filamin B and filamin C 




(FLNA, FLNB and FLNC) are highly conserved, and all three are expressed at high levels during 
development (Feng & Walsh, 2004). The filamin proteins themselves show 60-80% homology 
across their sequence except for the hinge regions, which are more diverse (Feng & Walsh, 
2004).  
The structure of filamin A is characterised by a highly-conserved N- terminal actin binding 
domain which is followed by 24 β-pleated ‘filamin repeats’, within which are two hinge regions 
(between repeats 15-16 and 23-24) that give the protein some flexibility (Robertson, 2005). 
Filamin A forms dimers at the C-terminal of the protein, at the 24th β-pleated repeat (Gorlin et 
al., 1990). This dimer forming C-terminal is critical to the function of the protein as, in addition 
to linking the dimer, many proteins that interact with Filamin A do so at the C-terminal 
(Robertson, 2005). Variants in FLNA can cause severe phenotypes, up to and including lethality 
(Robertson, 2005). For example, variants in the actin-binding domain or repeats 3, 10 or 14/15 
cause a spectrum of disorders including OPD-1 (Robertson et al., 2003). The structure of filamin 





















 The function of the filamins 
The filamin proteins operate by cross-linking actin filaments into networks or bundles to form a 
3D structure, which then aid in cell motility or otherwise alter cellular structure (Stossel et al., 
2001). In addition to binding actin, filamins have been shown to bind to upwards of 20 other 
macromolecules, including β-integrins and intracellular signalling components (Stossel et al., 
2001). Although the physiological effects of some of these interactions have not yet been 
discovered, almost all of those known have a role in providing mechanical stability in the cell 
membrane as well as the maintenance of the connections between cells (Stossel et al., 2001). 
Figure 1-2: The structure of Filamin A. Shown is a dimer connected at the C-terminal at the 24th β-pleated 
repeat. The Actin Binding Domain (ABD) is at the N-terminal of each half of the dimer and the hinge 




Filamins are thought to facilitate the occurrence of cellular processes, particularly those that 
require the polymerization of actin, by bringing together these diverse macromolecules. 
Variants in the genes that encode these filamin proteins are associated with a wide range of 
diseases, including Melnick-Needles Syndrome, OPD1, OPD2 and Larsen syndrome (Robertson 
et al., 2003). 
 Otopalatodigital Syndrome Type 1 (OPD1) 
OPD1 is an X-linked dominant genetic disease caused by gain of function variants in the FLNA 
gene, and is classified as a rare condition with an incidence of <1 in 100,000 individuals 
(Robertson, 2007). Its phenotype is the mildest of the OPD spectrum disorders and its 
characteristic features include dwarfism, spatulate fingers and toes, loss of hearing due to 
malformation of the ossicles in the ear, cleft palate and facial dysmorphisms such as a broad 
nasal root and frontal bossing (Dudding, 1967). There is no intellectual impairment in OPD1 
although there can be in other OPD spectrum disorders (Robertson, 2007).  
 Larsen Syndrome 
Larsen syndrome is an autosomal dominant osteochondrodysplasia normally caused by variants 
in Filamin B on chromosome 3 (Bicknell et al., 2007), but in rare cases it can be caused by 
recessive variants in the B3GAT3 gene. Larsen syndrome is characterised by congenital large-
joint dislocations and characteristic craniofacial abnormalities, including a prominent forehead 
and a flattened midface (Bicknell et al., 2007). In addition to these features, sufferers of Larsen 
syndrome also have spinal abnormalities such as scoliosis. Those affected by this syndrome 




1.4 The aims of this thesis 
This thesis aimed to determine the causative variants of these diseases in each of the selected 
families. If successful, it is possible that the results will greatly enhance our understanding of 
these diseases and their causes. In addition, it is likely that since the phenotypes are similar to 
those of typical OPD1 and Larsen syndrome, finding causal variants in other genes will indicate 
that those genes or their products interact with filamin or the filamin genes in some way. This 
means that finding these variants could elucidate more of the pathway of those genes and with 
what their products interact, giving us a greater understanding of the associated cellular 
processes. 
In addition, this thesis also aims to assess the use of whole genome sequence for identifying 
causal genes in cases that have otherwise been thoroughly investigated, as well as to implement 







2.1 DNA Samples and processing 
2.1.1 Obtaining samples 
Information regarding patients and their families was obtained from Professor Stephen 
Robertson, who had collected cases from collaborating centres. DNA had previously been 
extracted from peripheral blood samples and coded with their individual ID numbers. These 
samples were available from archival stocks in the Robertson Laboratory. The ethics approval 
under which these samples were used was 13/STH/56, Study title: Genetic and functional 
studies into the causation of congenital malformations.  
2.1.2 Whole Genome DNA Sequencing 
DNA samples were sent to the Kinghorn Centre in Sydney for whole genome sequencing. 
Sequencing libraries were constructed with the Truseq Nano DNA Library Preparation kit and 
run on an Illumina X Ten system using pair end sequencing with around 150 cycles. Subsequent 
reads were available as paired, gz-compressed, fastq format files for each individual. 
2.1.3 Sequence Processing for Alignment 
The compressed fastq files for each individual were checked for quality parameters using 
FastQC v0.11.2 (URL https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and then 
processed for alignment and variant calling according to the Genome Analysis Toolkit (GATK) 




genome GRCh37 (URL https://www.ncbi.nlm.nih.gov/grc/human/data?asm=GRCh37) using 
BWA v0.7.13 (URL https://github.com/lh3/bwa) with the mem algorithm. The primary 
alignment was then sorted and converted to bam format using the SortSam tool v2.3.0 from 
Picard (Li et al., 2009). Duplicated reads were identified with Picard MarkDuplicates (URL 
https://broadinstitute.github.io/picard/). Following this, tools from GATK 3.5 were used to 
realign around indels and perform Base Quality Score Recalibration to produce the completed 
alignment (bam format) for each individual.  
2.1.4 Confirming Identity and Family Relationships 
To confirm the identity of the individual under examination the GATK GenotypeConcordance 
tool was used according to the documentation online (URL https://software.broadinstitute.org 
/gatk/documentation/) to look for concordance between current (whole genome) and previous 
(exome) data, where exome data was available.  
To achieve this, a small “fingerprint” variant file (vcf format) was generated using GATK 
HaplotypeCaller in genotype mode to genotype selected loci with common polymorphisms in 
most populations. The collection of loci used was the HapMap 3.3 markers, with overall allele 
frequencies in that population between 0.3 and 0.7.  A threshold of 98% genotype concordance 
between exome and whole genome data was used to confirm identity. 
Following confirmation of identity, it was necessary to confirm that the relationships between 
the individuals in question were as recorded. Therefore, the GATK SelectVariants tool (version 




violations from each trio. If the relationships described in the pedigree are correct a low number 
of violations is expected. 
2.1.5 Variant calling and annotation 
 Determining gender 
The gender of each sample was determined from the sequence data in the bam file by 
calculating the number of X and Y chromosomes using depth of coverage comparisons between 
the true X and Y chromosomes and an autosome (chromosome 1) with the GATK 
DepthOfCoverage tool. Depth of coverage estimates were restricted to coding regions (using the 
Agilent SureSelect All Exon version 5 manifest) to minimise the uncertainty produced by largely 
non-coding polymorphic repeat variation on the Y chromosome.  
 Variant calling 
In the absence of conflict between the calculated and the reported gender, individual variant 
calling proceeded using the GATK HaplotypeCaller tool to produce a genomic vcf format file. The 
default ploidy of 2 was used for all regions except the true X region and the Y chromosome in 
males, where a ploidy of 1 was used to produce more representative genotype calls.  
 Compiling and quality control 
Following this, multiple samples were incorporated into a multi-sample vcf file using GATK 
JointGenotyper and then processed through GATK LeftAlignandTrimVariants. The multi-sample 
vcf file was then annotated with a variety of internally calculated metrics using GATK 
AnnotateVariants, and GATK VariantRecalibrator was used to perform Variant Quality Score 




tranches, by the probability that they are real. The highest tranche has the least false positives 
but is not very sensitive, and each subsequent tranche is more sensitive but has more false 
positives. The bands used in this study were 90.0 (estimated to identify 90% of true positives, 
missing 10% of them but not including almost all false positives), 99.0, 99.90 and 100 (i.e. all 
variants included). If a very high accuracy call set is required, then all variants outside the 
highest tranche can be removed, but if a more complete call set is a high priority then the lower 
tranches can be included.  
 Refinement 
 For the genotype refinement workflow, the autosomes were processed with GATK 
CalculateGenotypePosteriors to recalculate genotype quality after considering information from 
1000 genomes and from the respective pedigrees. GATK VariantFiltration was also used to mark 
genotypes with a genotype quality less than 20, and GATK VariantAnnotator was used to mark 
possible de novo variants. The sex chromosomes were not processed through the genotype 
refinement workflow as the tools do not work with non-diploid regions, but the unprocessed 
variants from these regions were reintegrated into the resulting multisample vcf file using GATK 
CombineVariants. 
 Annotation 
Gene context annotation and impact prediction was added using SnpEff 4.2 (URL 
http://snpeff.sourceforge.net/ SnpEff_manual.html) using Ensembl transcript data. SnpSift 4.2 
(URL http://snpeff.source forge.net/SnpSift.html) was used to add phastCons (URL 




dbNSFP 2.9 (URL http://snpeff.sourceforge.net/SnpSift.html#dbNSFP). GATK VariantAnnotator 
was used to transfer population allele frequencies from ExAC v0.3 (Lek et al., 2016) and (Auton 
et al., 2015), and clinical annotations from ClinVar 2016_01_04 
(https://www.ncbi.nlm.nih.gov/clinvar/intro/). These annotations were used selectively to filter 
variants for candidates. 
 Deletions 
2.1.5.6.1 The GenomeStrIP SV workflow 
As GATK HaplotypeCaller cannot be used to locate structural variants, it was necessary to use 
GenomeStrIP SV to find deletions (Handsaker et al., 2011). The GenomeStrIP SV release used 
was SV toolkit_2.00.1636, which has embedded within it GATK v3.5. GenomeStrIP SV requires at 
least 20 samples to be processed together, so the entire cohort of 145 whole genome samples 
available from other analyses in the clinical genetics group was processed together to produce a 
multisample vcf describing deletions in the cohort. These 145 individuals did not have the same 
disease as the individuals used in this analysis, nor were they relatives of patients with the same 
disorder. After the discovery and genotyping phases of the workflow default filters were used 
for the rest of the process. This workflow does not find all structural variants (only deletions). In 
addition, adequate annotation of allele frequencies cannot currently be obtained from sources 
such as 1000 genomes because the start and end positions of the deletions are approximate. 
This means that depending on the source you use, the deletions will be in slightly different 




2.1.5.6.2 Population construction 
The ambiguity in the breakpoints of the deletions makes it necessary to use individuals 
processed together throughout the genotyping phase of the SV workflow as the control 
population, so that any deletions have the same definitions. To accomplish this, a file was 
created using the collection of sequences available from the clinical genetics group that 
contained the whole genome data from unrelated individuals that do not have the disease of 
interest. This file contained the information from 87 individuals, giving an effective population 
size of 87. The values for allele number, count and frequency it contains were then used to 
annotate the file containing the family of interest so that similar filters to those used for short 
variants could be applied to deletions.  
2.1.1 Coverage and variant metrics 
Depth of coverage statistics for each individual were obtained from the bam files using the 
GATK DepthOfCoverage tool and a description of the SNPs and Indels was obtained in a variant 
call file using the Picard CollectVariantCallingMetrics tool (see Appendix one for results). 
2.2 Filtering Tools 
When using whole genome data huge numbers of variants are discovered, particularly in 
intronic and intergenic regions. This makes it necessary to reduce the number of candidate 
variants by applying different parameters a variant must meet to remain a candidate for causing 
disease. There are a wide variety of tools available to perform such filtering that can be used 
independently, in combination, or not at all, depending on the inheritance model being 




2.2.1 Population frequency filtering 
 Population frequency 
If a variant is present at an allele frequency higher than could account for the disease 
prevalence then it is unlikely to be causing the disease, which makes it useful to filter out 
variants present at a frequency higher than a set threshold in the general population. The 
selected allele frequency threshold depends on the penetrance of the disease, the inheritance 
model being investigated and the number of distinct variants in the population that cause the 
disease. To accomplish this, SnpSift was used to filter on allele frequencies in the ExAC and 1000 
genomes populations. In this case, the threshold frequency used was relatively conservative, as 
the more stringent the filter applied the more likely it is that the causative variant will be 
removed, so a conservative filter was applied then candidate variants were validated by 
sequencing using the Sanger methodology. 
2.2.1.1.1 The ExAC database 
One of the databases used to obtain the population frequency of the variants was the ExAC 
(Exome Aggregation Consortium) online database. This database contains the exome sequence 
of 60,706 unrelated individuals from multiple populations (exact numbers for population size 
are located at http://exac.broadinstitute.org/faq). The ExAC database contains a great deal of 
data on short variants, such as their location, gene and overall frequency in the combined 
populations. This makes it a very good resource for filtering out common variants, but as the 
disease in question may not be completely penetrant or an affected individual could have been 




rare in this database as opposed to simply not present. Another reason such filtering is 
necessary is because the disease could be recessive, in which case heterozygotes may be 
present.  
2.2.1.1.2 The 1000 genomes database 
The other database used to calculate the population frequency of the variants was the 1000 
genomes database. This database contains the genome sequence of 2504 individuals from 
multiple populations. The database contains information on short variants such as their overall 
frequency in the populations, location and gene. This database was used as it allowed filtering in 
the non-coding regions of the sequences used, which cannot be done with ExAC since it 
contains only exome data. 
 Separating individuals of interest from the cohort 
When filtering whole genome data for candidate variants it is possible to use the vcf containing 
the whole cohort, but for convenience it is more common to separate out the individuals of 
interest. This was accomplished using GATK SelectVariants version 3.6-0-g89b7209 to extract 
variant data for selected groups of individuals into a separate vcf file, which was then used for 
further filtering. 
 Variant quality 
2.2.1.3.1 Genotype quality 
Variants are assigned a genotype quality score that reflects the confidence that they are correct, 
and a low quality score is an indication that the call may be equivocal on the basis of there being 




filtered out if needed using the SelectVariants tool with the -select option, using the getGQ 
criterion. Often the genotype quality filter applied using Selectvariants is conservative, to 
reduce the risk of accidentally filtering out the causal variant. 
2.2.1.3.2 Truth sensitivity 
Another measure of quality that can be used to filter variants is the truth sensitivity tranche into 
which they fall. The truth sensitivity tranches separate out variants into four groups by the 
probability that they are real, and variants that fall into the lowest truth sensitivity tranche 
(VQSRTrancheSNP99.90to100.00) can be excluded using the -ef option in the GATK 
SelectVariants tool. This tranche has the highest rate of false positives, but when filtering out 
variants that fall into this tranche 0.1% of true positives will also be removed. In addition, this 
filter cannot be used for deletions as truth sensitivity scores are not calculated in that workflow. 
 Variant impact 
SnpEff impact scores were used to filter out variants predicted to have little or no effect on the 
function of a gene. This was accomplished by using SnpSift to filter such that only variants given 
a moderate or high impact were kept. Variants given a high or moderate impact score are 
usually missense or truncating variants. Filtering for impact scores reduces the area of the 
genome included in the analysis to an area where a variant has an effect on translated products 





2.2.2 Inheritance model filtering 
 The de novo model 
After separation of the trio of interest, a conservative list of de novo variants in the affected 
individual was created through filtering of the .vcf file using SnpSift. To filter for autosomal de 
novo variants, loci where the parents were both homozygous for the reference sequence, and 
the affected child showed a variant, were filtered for simultaneously. Using the SnpSift tool, this 
is done by keeping variants annotated as loConfDeNovo and hiConfDeNovo by the Genotype 
Refinement workflow in the affected child. As the workflow does not annotate de novo variants 
on the X chromosome it was necessary to filter for them separately. This was done using GATK 
SelectVariants to select bi-allelic variants where the non-reference allele was present in the 
affected individual, but not in either parent. GATK CatVariants was then used to combine the 
two resulting vcf files of de novo variants into one list of candidate de novo variants. It is 
possible that when using whole genome data too many de novo candidates to properly assess 
are found. In such cases, SnpSift was then used to filter for the predicted impact of the de 
novo’s found. Following this, SnpSift was also used to filter for variants with a low enough allele 
frequency in both the ExAC and 1000 Genomes databases.  
 The recessive model 
2.2.2.2.1 Homozygous 
To create a list of possible homozygous variants, SelectVariants was used to simultaneously 
filter for locations where the affected individual was homozygous variant and both the mother 




with the –select option, using the getGQ criterion. SnpSift was then used to filter for variants of 
sufficient rarity in both the ExAC and 1000 Genomes databases. Following this, the remaining 
candidate variants were filtered on their predicted impact, again using SnpSift.  
2.2.2.2.2 Compound Heterozygous 
To find compound heterozygosity it was necessary to filter for genes where there were two 
candidate variants in the same gene, one inherited from the father and the other from the 
mother. This was accomplished by first using SelectVariants to simultaneously filter for locations 
where the child and father were heterozygous but the mother was homozygous reference. Then 
SelectVariants was used to filter for locations where the child and mother were heterozygous 
but the father was homozygous reference. 
Following this, a list of the genes that contained the remaining variants from the father was 
created, as well as one containing the variants remaining from the mother. To do this the 
annotation of transcript names created earlier by SnpEff 4.2 was used. After creating these lists, 
they were compared and any gene that contained at least two candidate variants in the child, 
where one candidate was inherited from the father and the other from the mother, was placed 
into a final list of genes that could be affected by compound heterozygosity. The final list was 
then further filtered to only include rare variants using SnpSift, after which low quality variants 






After annotation through the GenomeStrIP SV workflow and construction of the population file, 
a file containing the data for just the trio of interest was created. This file contained information 
on deletions in the individuals in the same way that the files created through GATK 
HaplotypeCaller contained information on short variants. These files were then used to look for 
deletions that met the criteria for the same models as the short variants. 
 de novo deletions 
To filter for de novo deletions, the vcf containing information on the deletions present in the 
trio was filtered as for de novo short variants. This involved filtering for locations where the 
child carried a deletion compared to the reference sequence but both parents did not, using 
GATK SelectVariants, followed by using SnpSift to filter out variants present at too high a 
frequency in the control population.  
 Recessive deletions 
2.2.3.2.1 Population frequency filtering for deletions 
As there is some ambiguity in the breakpoints of deletion variants it is necessary to construct a 
population of individuals processed together during genotyping for use as the control 
population. Therefore, a file was created that contained from individuals in the cohort of 
available sequences that are unaffected by the disease of interest. This file was then used to 
annotate the file containing the family of interest so that similar filters used for short variants 
could be applied to deletions. However, as the number of individuals in the control population 




this, instead of using allele frequencies in the control population, allele counts were used, 
where if a variant was present more than once in the control population it would be excluded as 
a candidate for being too common. This filter was applied using the SnpSift tool. 
2.2.3.2.2 Homozygous 
In order to locate any homozygous deletions in the child, a filter that kept only locations where 
the child was homozygous and did not match the reference sequence was applied using GATK 
SelectVariants. This list was then further filtered to only include rare deletions using SnpSift. In 
addition to filtering for rarity, candidates that were not of sufficient quality were filtered out 
using the –ef option in the SelectVariants tool. 
2.2.3.2.3 Compound heterozygous 
To find locations where a deletion could be causing compound heterozygosity, it was necessary 
to filter for deletions that were close enough to a gene that it could affect its function, where 
that gene also had another candidate variant. This was accomplished by filtering for 
heterozygous variants that could affect gene function within one megabase (1,000,000bp) of 
either side of the approximate breakpoint of a heterozygous deletion. One megabase was 
chosen as the distance a deletion could be from a variant while still potentially affecting the 
gene containing the variant, because previous literature has suggested that enhancers can be 
up to a megabase from the gene they affect (Pennacchio et. al., 2013). Any variants located 
within that distance were then further filtered to remove variants that were too common in the 
ExAC and 1000 Genomes databases using SnpSift. In addition to filtering for rarity, variants that 




2.3 Selection and vetting of candidates 
2.3.1 The VCF file 
Following filtering, a relatively short list of variants remained in a vcf from each model, including 
both real variants and some false positives. These files were manually examined to determine 
which of the remaining variants should be considered candidates for causality. Factors used to 
decide included the gene the variant was in, realistic values for allele number and a low 
frequency in the populations used. In addition, as it is known that the workflow has difficulties 
aligning around repeat elements such as microsatellites, variants in those areas were 
considered less likely to be real.  
2.3.2 IGV browser 
Another way the list of variants was vetted to remove variants not likely to be causative was 
using IGV (Integrated Genomics Viewer) to examine depth of coverage and read quality, as well 
as to see if the values in the vcf file for allele number matched up (Thorvaldsdottir et al., 2013). 
IGV shows if the pairs of reads are discordant, a histogram of the number of reads at any given 
base, and the base call for each position. Figure 2-1 is an example of a typical screen in IGV. If 
IGV showed low quality reads, low coverage, that one allele was much more common than the 
other, or that the variant was within (or at the end of) a repeat element it was considered less 






















































































































































































































The IGV browser was also used to assess deletions that were found using paired end reads. 
Paired end reads will normally be aligned close to each other, but in the event of a deletion the 
pairs of reads are often not able to align correctly, and one of the two is often displaced. When 
this occurs IGV highlights the reads in red and labels them discordant. This can then be used to 
find deletions by eye, as if a deletion is suggested by the workflow and there are two well 
defined blocks of discordant reads, it is a good indication that the deletion is real, while if no or 
few reads are discordant it suggests that there is no deletion. In addition to discordant reads, 
IGV showing a drop in coverage to either half of the average number of reads or no reads at all 
is a good indication of a deletion being present. An example of discordant reads and a drop in 
coverage indicating a deletion can be seen in figure 2-2. 
 
Figure 2-2: An example of a large number of discordant reads and a drop to half of the average coverage in IGV 
indicating a heterozygous deletion. The discordant reads are red, shown either side of the deletion below the grey 






2.3.3 Gene function 
If a variant was found in a gene that had a function known to be involved with the phenotype 
shown by the affected individual, as well as meeting the other requirements, it became a strong 
candidate. On the other hand, if the variant was in a gene known to tolerate loss of function or 
accrue variants at a high rate, such as the T-cell receptor genes, it was considered less likely to 
be causal. If a candidate variant was intronic and had no clear significance in causing disease, i.e. 
was not likely to affect splicing or another regulatory element, it was also excluded as otherwise 
there would be too many candidate variants remaining to reasonably analyse through a 
secondary sequencing methodology. 
2.3.1 ExAC browser 
In addition to gene function, the ExAC prediction of how likely it was that the gene could 
tolerate a variant that could cause loss of function was used to determine if a variant in a 
certain gene was a candidate for causing the phenotype seen. The ExAC database defines a 
variant as causing Loss of Function (LoF) if it is a nonsense, splice acceptor, or splice donor 
variant caused by single nucleotide changes (Lek et al., 2016). ExAC assigns each gene a score 
between 0 and 1 based on the number of expected variants of these types compared to the 
number observed. The closer the LoF intolerance score is to one, the less likely it is that the 
gene can tolerate loss of function. Any gene with a loss of function tolerance below 0.4 as 
calculated by ExAC was excluded as unlikely to be a cause of dominant genetic disease. For 




function variants present in the gene was used instead. If high-confidence homozygous loss of 
function variants were present, variants in that gene were excluded.  
2.3.2 UCSC Genome Browser 
For the deletion variants, the start and end positions given in the vcf were entered into the 
University of California Santa Cruz (USCS) Genome Browser (URL: http://genome.ucsc.edu/). 
This genome browser contains information on deletions from the Database of Genomic Variants 
(DGV), which contains information from ExAC and 1000 genomes (Kent et al., 2002). If multiple 
deletions with similar breakpoints (within 100bp of either end) to the candidate deletions were 
present then the deletion was deemed too common to be causative. 
2.4 HGVS (Human Genome Variation Society) nomenclature 
Following vetting of the candidate variants, standardised nomenclature was constructed to 
describe them using the HGVS system. The HGVS system is comprised of three names. The first 
describes the genomic position of the variant, the second which transcript contains the variant 
and its position within said transcript, and third describes the predicted change the variant will 
cause in the protein produced. If the candidate variant was intronic no protein level name was 
constructed as the effects of the variant on the protein produced could not be predicted. This 
nomenclature makes it easy for others to locate the variant in question themselves as well as 
see the effect it is predicted to have at a glance. The HGVS nomenclature for each candidate 
variant was constructed following the HGVS guidelines (den Dunnen et al., 2016). In addition, 
Mutalyzer version 2.0.25 was used to aid in constructing the names (Wildeman, van Ophuizen, 




2.5 Sequencing for variant confirmation using the Sanger methodology 
2.5.1 The Polymerase Chain Reaction 
 Primer Design 
Primers flanking a candidate variant were chosen using Primer 3 version 4.0 (Untergasser et al., 
2012), before checking for multiple priming sites using the In-Silico PCR tool on the UCSC 
website (URL https://genome.ucsc.edu/cgi-bin/hgPcr). They were then ordered from Integrated 
DNA Technologies (IDT) and diluted to 5µM before use. 
 Optimisation  
An optimisation reaction was run on a temperature gradient for the primer annealing step 
between 52°C and 64°C using control human DNA to determine the best temperature to use for 
the real reaction. The temperature that produced the highest quality PCR product was 
subsequently used for each reaction. The optimisation program consisted of: 
1. Incubation at 94°C for 4 minutes. 
2. Incubation at 94°C for 30 seconds. 
3. Gradient across the wells from 52°C to 64°C for 30 seconds. 
4. Incubation at 72°C for 1 minute. 




 Reaction Conditions 
Following optimisation samples were run in a PCR machine at the optimal annealing 
temperature for each reaction, as determined by the optimisation reaction. This program 
consisted of: 
1. Incubation at 94°C for 4 minutes. 
2. Incubation at 94°C for 30 seconds. 
3. Incubation at optimal annealing temperature for 30 seconds. 
4. Incubation at 72°C for 1 minute. 
5. Repeat steps 2 to 5 35 more times and end. 
2.5.2 Gel electrophoresis 
After PCR, the samples were run for 30 minutes at 10V/cm in a 2% agar gel in 0.5XTBE 
containing 0.5 µg/mL ethidium bromide, before being visualised on a UV transilluminator to 
determine if amplification had occurred successfully. In addition to the samples, a standard 
100bp ladder was used to aid in visualising length. Success was determined based on the 






2.5.3 Confirmation by sequencing using the Sanger methodology 
 Pre-sequencing 
If gel electrophoresis showed sufficient amplification of the samples for sequencing, a pre-
sequencing reaction was used to clean up the PCR products before the sequencing reaction. 
First, 0.7µL of 5x sequencing buffer (composed of 0.4M Tris-HCL with a pH of 9.0 and 10mM 
MgCl2), 0.075µL of Exonuclease 1 (Biolabs, 20U/µL), and 0.4µL shrimp alkaline phosphatase 
(USB, 1U/µL) was added to 2 µL of PCR product. This was then made up to a total volume of 5 µL 
using distilled water. The reactions were then incubated at 37°C for 15 minutes before a further 
15-minute inactivation step at 80°C in a thermal cycler. 
 Sequencing 
Following the pre-sequencing reaction, the reactions were made up to a 10µL final volume 
through the addition of 0.6µL of Big Dye Ready Reaction Mix (ABI), the appropriate sequencing 
primer (0.16µM final concentration), and the appropriate volume of distilled water. The 
sequencing primers were either the forward or reverse primer used to amplify the sample 
during PCR. The reactions then underwent a thermal cycler step consisting of 25 cycles of: 95°C 
for 10 seconds, 50°C for five seconds, and 60°C for four minutes. Following this the samples 
were precipitated by adding 62µL precipitation mix (consisting of 77.5% ethanol and 10mM 
sodium acetate) followed by centrifuging at 4000rpm for 10 minutes in a plate centrifuge with 
an 18cm radius. The resulting supernatant was removed and the pellet washed with 100µL of 




supernatant was again removed and the pellet was then left to air-dry upside down, with no 
light exposure for a minimum of 30 minutes. 
The samples were then resuspended and sequenced by the Genetic Analysis Services 
(Department of Anatomy, University of Otago, Dunedin) using a 3730xl DNA Analyzer. The 
resulting chromatograms were then visualized using FinchTV version 1.4.0 (URL 
http://www.geospiza.com/Products /finchtv.shtml). Candidate variants were located manually 





3 A case of unexplained OPD1 syndrome 
3.1 The OPD1 family 
In 1999, a family with a child affected by an unusual case of OPD1 was referred to Professor 
Stephen Robertson while the gene that caused OPD1 was still unknown (personal 
communication). The affected individual from this family presented a very severe OPD1 
phenotype, with the addition of intellectual impairment, and was therefore clinically diagnosed 
with severe OPD1. The parents were unaffected (see figure 3-1). Since the time of this patient’s 
referral, variants in FLNA have been established as a cause for OPD-1, and in all other families 
with this diagnosis that have been examined the disorder can be accounted for by variants in 
this gene. The causal variants are usually small deletions or missense variants that alter the 
filamin A protein (Robertson et al., 2003). To attempt to determine the variant causing such 
severe OPD1 in this individual, the exons of the FLNA gene had been extensively sequenced 
using the Sanger methodology, but no variant that could cause disease was found. In addition to 
sequencing of the FLNA gene, array-CGH had been performed, but again no causative variant 
was discovered.  
The failure of the CGH array, as well as sequencing of the FLNA gene using the Sanger 
methodology, to discover a causative variant in this family makes it likely that the causative 
variant is in a different gene, which would be unknown in the history of OPD1 cases. Finding the 













3.2 Confirmation of family relationships 
First, it was necessary to confirm that the relationships between the three individuals in the trio 
were as recorded. This was because models based on Mendelian inheritance will be used to 
attempt to find the disease-causing variant in the affected child. If for some reason, such as the 
wrong individual being collected or mislabelling of the sample or file, the wrong samples were 
used in the analysis then the analysis would be invalid.  
To confirm that the three individuals were in fact mother, father and child, the number of 
Mendelian violations at biallelic autosomal variants present in the trio was calculated. There 
were 238 Mendelian violations found. In order to determine if this was within the acceptable 
range for a family trio relationship, the process was repeated with an altered pedigree, where 
Figure 3-1: A visual representation of the pedigree of the trio affected with OPD1. The affected individual is 
coloured in black. Circles are female while squares are male. In this family both the mother and father are 






the child from the Larsen family (see section 4.1) was substituted instead of the child from this 
family. This produced 1390516 Mendelian violations, which showed that the 238 found was 
within the acceptable range and the relationships were consistent with those recorded. 
3.3 Investigation of the FLNA gene region 
As all previous cases of OPD1 for which a molecular diagnosis has been obtained have been 
caused by variants in the FLNA gene, any variants found in the FLNA gene that could be causal 
would be prime candidates to be causing the disease in the child. Therefore, the FLNA gene 
region was examined to locate any variants in the gene that could be causative. One de novo 
variant was found in the FLNA gene in the affected individual, but it was not located in a coding 
sequence. It also fell within the VQSRTrancheSNP99.90to100.00 truth sensitivity tranche, which 
suggested that there was a high chance it was a false positive. Upon viewing the variant in IGV it 
was found that the variant was in an area of low coverage at the end of multiple reads (see 
Appendix two), and many of the partners of the reads at this location were mapped to other 
chromosomes, suggesting that there is an issue with mapping to this location. Because of this, it 
was deemed unlikely to be causing this individual’s OPD1. 
As there was no candidate variant found in the FLNA gene in this individual, it was necessary to 




3.4 Investigation of a de novo variant model for SNVs, short insertions 
and deletions (short variants)  
3.4.1 Filtering for de novo variants 
Although the inheritance in this family could be interpreted in a number of ways, the simplest 
hypothesis is a de novo variant producing a dominant trait. De novo variants are of particular 
interest because only a small number are expected to occur in a child, so when a disease 
previously unknown in the family appears at the same time, they become good candidates for 
investigation as to whether they are causative. Therefore, to determine if any de novo variants 
that could be causative were present in the affected child, the genomic data was filtered to find 
any locations where the mother and father matched the reference sequence but the child did 
not, where the variant was likely to have an impact on gene function. In addition to filtering for 
de novo variants, the data was filtered to exclude variants present at an allele frequency of 
greater than 0.001 in either the ExAC or 1000 Genomes databases. In addition to filtering for 
rarity, only variants that were annotated as having either a high or moderate impact according 
to their classification by the SnpEff tool were retained after filtering. Variants classified as such 
by SnpEff are those that are predicted to change the amino acid sequence of the resulting 
protein in some way, which makes them good candidates for causing phenotypic changes. 
There were five de novo variants listed as high impact and 18 as moderate. Of these several 
appeared to be artefacts and many were excluded for other reasons (see Appendix three). For 
example, there were two suggested de novo variants in the MTMR1 gene, but they occurred 




have difficulties aligning around repeat elements such as microsatellites, and PCR has issues 
with slippage when sequencing such areas, these variants were excluded. Another candidate de 
novo variant eliminated was a loss of function variant in the TRIP10 gene, as TRIP10 has a 
tolerance of loss of function score of 0.35 in the ExAC database. This means that the TRIP10 
gene is known to have a high tolerance for loss of function variants and as such this variant was 
unlikely to be causing the disease seen in the affected child. 
Of the three variants not excluded, one listed as high impact was in a splice donor site for exon 
20 of the CREBBP (CREB Binding protein) gene (HGVS transcript NM_001079846.1:c.3665+1G>C). 
Variants in the CREBBP gene are known to cause Rubinstein-Taybi syndrome (Rubinstein & Taybi, 
1963), a disease with some features similar to OPD-1 with the addition of mental retardation. 
The other two remaining candidates were single base substitutions in RBMXL3 (HGVS protein 
NM_001145346.1(RBMXL3_i001):p.(His860Arg)) and USP17L11 ( HGVS protein 
NM_001256854.1(USP17L11_i001):p.(Phe29Val)). Both of these variants were listed as 
moderate impact, and neither of these genes had been previously associated with any disorders. 
Not much information was available about the function of these genes, which made them hard 
to assess. Many of the reads covering the USP17L11 variant had a mapping quality of zero, 
which meant that there was more than one location in the genome that they were equally able 




Both the CREBBP and RBMXL3 variants looked plausible in IGV, as they were not in a repetitive 
region and had adequate read depth and good allelic balance (see figure 3-2). These variants 
were therefore considered to be reasonable candidates, but the CREBBP variant was considered 
to be more likely as it was in a known disease gene, where the disease had features similar to 
OPD1, and the variant would disrupt splicing. Therefore, the area around and including the 
CREBBP variant was sequenced according to the Sanger methodology to confirm its presence. 
Figure 3-2: The RBMXL3 and CREBBP variants as seen in IGV. A is the RBMXL3 variant, while B shows CREBBP. In both 





3.5 Investigation of a de novo model for deletions 
In addition to searching for short de novo variants, larger de novo deletions were filtered for 
using the data generated from GenomeStrIP SV. To locate de novo deletions a filter was 
constructed that found any locations in the genome where there a deletion was present, and 
the mother and father matched the reference sequence, but the child did not. Deletions that 
appeared more than once in the control population were also filtered out, and in addition to 
filtering for rarity, candidates that were not of sufficient quality (i.e. those that did not meet the 
PASS criteria from GenomeStrip) were filtered out. After filtering, five candidate deletions 
remained, of which four were not convincing after examination of the coverage in the IGV 
browser for this trio due to the low number of discordant paired-end reads, high numbers of 
reads with a mapping quality score of 0, and large numbers of low quality reads surrounding the 
deletion. The remaining one, however, was 122,284bp long and resulted in the deletion of four 
entire olfactory receptor genes on chromosome 1 (see figure 3-3). Although de novo deletion 
variants are rare (only four convincing de novo deletion variants were found using GenomeStrIP 
SV in a population of 87 trios for which data was available), it was decided that this deletion was 
unlikely to be causing the phenotype seen in the affected individual. This decision was made 
due to the nature of the genes deleted and the fact that a variant very likely to be causative of 





3.6 Confirmation of CREBBP de novo variant 
Sequencing across the location of the suspected CREBBP variant according to the Sanger 
methodology confirmed the CREBBP variant, and therefore that the affected individual almost 
certainly has Rubinstein-Taybi syndrome and not OPD-1 (see figure 3-4).  
Figure 3-3: An image showing the de novo deletion found in individual 182 that deletes four olfactory receptor genes, 
as seen in IGV. It is 122,284bp in length. The arrows indicate the approximate breakpoints at either end of the 
deletion. However, due to the nature of the genes deleted this deletion is unlikely to be causing the phenotype seen 
in the affected individual. 
Figure 3-4: The chromatogram produced during validation of the CREBBP variant by sequencing using the Sanger 
methodology. The variant is indicated by the arrow and is heterozygous. The chromatogram was produced using 





The Human Genome Variation Society nomenclature for this variant at the genomic and 
transcript levels is in Table one. As this variant is a splice donor variant, it is difficult to predict 
the effects of the variant on this protein. There are two main possibilities; the variant could 
cause readthrough into the next intron, which may then be translated until a stop codon is 
encountered, or it is possible that increased skipping of the exon may occur. If the variant 
causes readthrough into the intron, it is predicted that the protein will truncate almost 
immediately (HGVS protein NM_001079846.1(CREBBP_i001):p.(Thr1223*)). In the event that a 
premature stop codon was created, it is likely that nonsense mediated decay would occur, and 
no protein would be produced. The other possibility is that the variant would cause the exon to 
be skipped with increased frequency. As the length of the exon is a multiple of three bases, 
skipping it would result in an in-frame deletion in the protein. The HGVS protein nomenclature 
for this would therefore be NM_001079846.1(CREBBP_i001):p.(Tyr1196_Thr1222del). 
Even though the exact effects of this variant on the protein are difficult to predict, it is likely that 
they will cause loss of function. 
Table 1: The Human Genome Variation Society nomenclature for the CREBBP variant at the genomic and transcript 
levels. The protein level name could not be produced, as the exact effect of this variant on the protein could not be 
predicted. It is likely, however, that the variant will cause loss of function of the protein, as it affects a splice donor 
site. Tolerance of LoF (loss of function) is the score given by the ExAC database to show how likely the gene is to be 





















As the variant in CREBBP was confirmed by sequencing using the Sanger methodology and 
predicted to truncate the protein produced, it was concluded that this individual has Rubinstein-
Taybi syndrome instead of OPD-1, and that the initial diagnosis was mistaken. 
It is possible that the initial diagnosis was incorrect, and remained uncorrected for such a long 
time, for multiple reasons. Firstly, the case occurred before the OPD spectrum of disorders was 
well defined and before the techniques used here were developed. In addition to this, the 
diagnosis was made using second hand information (a description of the affected individual with 
no images). Finally, OPD1 and Rubinstein-Taybi have some overlap in their phenotypes which 
can make them difficult to distinguish. For example, individuals affected by either OPD1 or 
Rubinstein-Taybi often have broad thumbs and generalised bone dysplasia, in addition to short 
stature. 
Although it is slightly disappointing that this is a relatively trivial explanation for the case and it 
doesn’t illuminate any new biology as was initially hoped, this finding provides value to the 
family concerned in terms of a more confident diagnosis and a more accurate prognosis. For 
example, individuals affected by Rubinstein-Taybi have been found to be more susceptible to 
tumour formation and cardiac abnormalities (Miller & Rubinstein, 1995). Knowing about these 





4 A case of unexplained Larsen syndrome 
4.1 The Larsen Family 
The second family in this investigation also consists of unaffected parents with an affected child 
(see figure 4-1). The child was diagnosed very early on to have the phenotype typical of Larsen 
syndrome, with scoliosis and joint dislocations, with the additional trait of weak teeth prone to 
chipping, which has not previously been described in association with Larsen Syndrome 
(Robertson, personal communication). The weak teeth may be coincidental, but as unusual 
traits such as this are often diagnostically useful, it may be a possible clue to assist new gene 
identification. For all individuals diagnosed with Larsen syndrome for which a molecular 
diagnosis has been obtained, a causal variant has been found in either the FLNB gene (in the 






0 Figure 4-1: A visual representation of the pedigree of the trio affected with Larsen Syndrome. Clear shapes are 
unaffected individuals while the affected individual is coloured black. Circles are female while squares are male. In 




However, in the case of this family no causative variant has been found despite a thorough 
search. Initially the exons and the exon-intron boundaries of FLNB had been sequenced 
individually using the Sanger methodology. In addition, MLPA was performed over the gene, but 
no causative variant was found (Robertson, personal communication). Following this, array CGH 
was performed using the Aligent 180k oligoarray platform, but again nothing likely to be causal 
was found. Finally, in 2014 the exomes of the affected child and their parents were sequenced, 
but again no convincing variants were found under either dominant or recessive models of 
analysis.  
Since such thorough techniques have been unable to find a cause for the Larsen syndrome in 
this family, it is likely that, as in the family affected by OPD1, the Larsen is of novel cause. Also, 
as the exomes of the family have been examined previously it is possible that the cause is 
outside of the coding region of the genome. This means that finding the variant causing Larsen 
disease in this family could give us insight into how the filamin genes are regulated or with what 
they interact, helping us understand the pathway of which they are a part. 
4.2 Confirmation of family relationships 
As for the OPD1 family, it was necessary to confirm that the relationships between the three 
individuals in the trio were as recorded. This was because models based on Mendelian 
inheritance will be used to attempt to find the disease-causing variant in the affected child. If for 
some reason, such as the wrong individual being collected or mislabelling of the sample or file, 
the wrong samples were used in the analysis then the analysis would be invalid. To confirm that 




Mendelian violations present in the trio was calculated. There were 260 Mendelian violations 
found. In order to determine if this was within the acceptable range for a first-degree 
relationship, the process was repeated with an altered pedigree, where the parents from the 
OPD1 family were substituted into the trio from this family. This produced 1390516 Mendelian 
violations, which showed that the 260 found was within the acceptable range and the 
relationships were consistent with those recorded. 
4.3 Investigation of a de novo variant model for SNVs, short insertions 
and deletions (short variants) 
4.3.1 Filtering for de novo variants 
As for the family affected by OPD1, the simplest hypothesis for what is causing the disease in 
this family is that of a causal de novo variant. As before, the genomic data was filtered for 
locations where both the mother and father matched the reference sequence but the child did 
not. Variants present at an allele frequency of greater than 0.001 in either the ExAC or 1000 
Genomes databases were excluded. In addition to filtering for rarity, only de novo variants were 
annotated as having either a high or moderate impact were kept. 
As variants in the FLNB gene have been found to be responsible for causing dominant Larsen 
syndrome in every family for which a molecular diagnosis has been obtained, any de novo 
variants found in the FLNB gene would be excellent candidates to be causative in this family. 
Therefore, the list of variants that remained after filtering was examined for any variants in the 




surrounding regions of a megabase either side, so de novo variants across the rest of the 
genome were examined. This distance was chosen as it has previously been described that 
enhancers can be up to a megabase from the gene they affect (Pennacchio et al., 2013). 
4.3.2 Remaining candidate de novo variants 
Across the rest of the genome there were seven de novo variants that remained after applying 
the filter above. Of these, six were deemed unlikely to be causal for any of a number of reasons, 
such as the gene being likely to tolerate loss of function mutations. For example, one of the 
suggested de novo variants was in the MUC4 gene, which is known to normally be variable 
without causing a deleterious phenotype. Another candidate de novo variant removed was in 
the FAM186A gene, and was located in a cluster of a large number of common variants (four 
common variants within five bases of the variant, in addition to one allele being much more 
common than the other. This unusual clustering of suggested variants and lack of allelic balance 
made it likely that the candidate variant was an artefact of alignment, so it was excluded. A list 
of the excluded candidate variants can be found in Appendix four. The remaining candidate de 
novo was in the ASXL3 gene on chromosome 18 at base 31,319,283 and is a T>C substitution 
predicted to change a Serine to a Proline in the resulting protein. ASXL3 has a loss of function 
tolerance score of 1.0 in ExAC, which means that it is predicted to be highly intolerant of loss of 





Table 2: Gene name and genomic location for the remaining candidate variants from all different models after 
filtering as well as their HGVS standardised names. The number of homozygous LoF variants in ExAC shows how 
many high-confidence LoF variants were present in the ExAC database. If such variants were present it was more 
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4.4 Investigation of recessive models for short variants 
4.4.1 Filtering for recessive variants 
As the de novo candidates discovered in this family were not certain to be causative, it was 
necessary to continue to search the genome for likely variants. Therefore, a model to filter for 
recessive variants, both homozygous and compound heterozygous, was constructed. 
 Homozygous variants 
In order to find variants where the affected child had inherited a homozygous variant from the 
parents, the genomic data was filtered to find locations where the affected individual had a 




down the list of candidates to a manageable number it was necessary to exclude variants with a 
genotype quality of less than ten, as such a low quality score indicates low confidence that the 
base call is accurate . Variants present at an allele frequency of more than 0.001 in either the 
ExAC or 1000 Genomes databases were also removed. The candidate variants were also filtered 
on their impact; all variants other than those predicted to have a high or moderate impact were 
removed.  
After this filtering, there were 21 homozygous variants across 15 genes, of which only one 
remained as a candidate after further examination. For example, three loss of function 
candidate variants in the NBPF10 gene were excluded because individuals in the ExAC database 
have previously been found to have homozygous loss of function variants in that gene, without 
a severe developmental disorder. This makes it unlikely that the recessive loss of function 
variants in the NBPF10 gene in this family are causing the deleterious phenotype seen. Another 
variant removed after further examination was in the FIGN gene, and was removed as it 
occurred in a microsatellite repeat, which meant that it was probable that the variant was due 
to either slippage during PCR or an error during the alignment process. The full list of variants 
and their reasons for exclusion can be found in Appendix five. 
 Compound heterozygous variants 
To find variants where the affected child had inherited a heterozygous variant from one parent, 
in addition to a different heterozygous variant within the same gene from the other parent, the 
genomic data was filtered to simultaneously select for locations where the child and father were 




mother were heterozygous but the father was homozygous reference were filtered for. 
Following this a list was made of all the genes where the child had inherited at least one variant 
from the mother, as well as at least one variant from the father. This list was then further 
filtered to include only variants that were not present or were present at a frequency of less 
than 0.001 in the ExAC and 1000 Genomes populations. Variants of low quality were also 
removed by excluding VQSRTrancheSNP99.90to100.00, as well as by removing all variants with 
a genotype quality of less than 10. 
After filtering, there were 74 compound heterozygous variants across 24 genes, of which two 
remained as candidates after further examination. These are defined in Table two. The other 
candidates were excluded for a variety of reasons; for example, three candidate variants 
remained after filtering in the NBPF10 gene, but in the ExAC database there are multiple benign 
homozygous loss of function variants recorded that are different to the candidates found in this 
analysis, one of which occurred 36 times. This makes it likely that NBPF10 is able to tolerate 
homozygous loss of function without causing a deleterious phenotype, so the variants in 
NBPF10 were removed from the list of candidates. Other candidates, such as two in PIK3AP1, 
were excluded because they were located in microsatellites, which meant that it was probable 
that the variant was caused either by slippage during PCR or an error during the alignment 
process. Another pair of candidates excluded was the pair of variants in the TRBV10-1 gene. 
These variants were excluded because the TRBV10-1 gene is a T-cell receptor gene, which 
means that it is normally highly variable (Wilson et. al., 1988). The full list of variants and their 




4.4.2 Remaining recessive candidates 
 Homozygous candidates 
After further examination of the candidate homozygous variants to determine if they could be 
causal there were none that remained as a candidate for causality. 
 Compound heterozygous candidates 
After further examination of the candidate variants that fit the compound heterozygosity model 
to determine if they could be causal, two pairs remained as candidates that required 
confirmation. Details of these variants can be found in table two. 
4.5 Investigation of a de novo model for deletions 
As for the OPD1 family, the genomic data of the trio affected by Larsen syndrome was examined 
for the presence of deletions detected using the GenomeStrIP SV workflow as described in 
methods section 2.2.3. The deletion data was then filtered to locate variants that fit various 
inheritance models, the first of which was that of de novo deletions responsible for a dominant 
trait. In order to find de novo deletions, locations where the child carried a deletion compared 
to the reference sequence but both parents did not were found. Following this, variants that 
were seen more than once in the control population were removed, as they were deemed to be 
too common. There were no de novo deletions found in this family, so a model to find deletions 




4.6 Investigation of recessive models for deletions 
4.6.1 Filtering for deletions with possible recessive effects 
The second model examined using the deletion data was that of deletions with possible 
recessive effects, including both homozygous and compound heterozygous situations. In the 
case of compound heterozygous contributions, the hypothesis was that there was an inherited 
heterozygous deletion within a gene or close enough to one to possibly affect its function from 
one parent, and the affected gene also contained a short variant inherited from the other 
parent that could be affecting its function. Combined this could make the gene non-functional. 
The short variants considered as candidates in combination with a deletion were filtered to only 
include those predicted to have a high or moderate effect on a protein, even though doing so 
risked missing a possible causal intronic or intergenic variant. This was necessary due to the 
large number of variants outside coding regions that would otherwise have remained as 
candidates, many of which would be impossible to evaluate with regards to their ability to affect 
gene function. In addition to genes containing a deletion, genes within a megabase of the 
approximate breakpoint of a heterozygous deletion were included as it was possible that the 
deletion damaged a regulatory element such as an enhancer. 
 Homozygous deletions 
There was one homozygous deletion identified in the affected child, located on chromosome 8 
approximately between bases 70,319,872 and 70,325,202. The closest gene to this deletion is 
LINC01603, which is between bases 70,337,106 and 70,360,479 and is a long intergenic non-




deletion was previously found in five individuals out of 1151 in the 1000 Genomes phase one 
database (URL http://dgv.tcag.ca/dgv/app/variant?id=esv2673314&ref=hg19). The overlap in 
location of these deletions suggests that they are the same as the candidate deletion, which 
made it too common to be considered a candidate for causality of a rare but highly penetrant 
single gene disorder. 
 Compound heterozygous deletions 
There were 21 heterozygous deletions detected in the affected child. None of the deletions 
contained any exons and none obviously affected splice sites in the NCBI RefSeq transcript 
database (URL https://www.ncbi.nlm.nih.gov/refseq/). Of the 21 deletions, only one was within 
one megabase of a gene, in addition to that gene containing a possible variant predicted to 
affect its function. The gene, called C18orf61, was roughly 500,000 bases away from the 
deletion and contains a short variant predicted to affect splicing. 
4.6.2 Remaining recessive deletion candidates 
For these reasons, of the 22 deletions found only one was considered a candidate to be causing 
the disease in this family, in combination with a variant in a gene of unknown function called 
C18orf61. The deletion is roughly 1470 base pairs long between bases 11,730,592 and 
11,732,061 on chromosome 18 within an intron of GNAL (G protein subunit alpha L) (reference 
genome GRCh37/hg19). This location is just an estimate as the exact breakpoint of the deletion 
cannot be accurately determined to within 50bp at this time. The variant that in conjunction 
with this deletion is a candidate is an intronic A>G substitution predicted to affect a splice donor 




uncharacterised open reading frame (ORF) of unknown function located on chromosome 18 
between bases 12200778 and 12224710 of transcript NC_000018.9 (reference genome 
GRCh37/hg19). Because nothing is known about the function of C18orf61 or how it could be 
affected by the deletion in question, it is difficult to evaluate this variant. This means that 
although the variant in C18orf61, in conjunction with the intronic GNAL deletion, remains a 
candidate it is of low priority and was not sequence validated.  
4.7 Confirmation of the remaining candidates 
The candidates that remained after both filtering and further examination were then validated 
by sequencing using the Sanger methodology. Of those, several were found to have been false 
positives and were therefore eliminated as candidates, including a pair of compound 
heterozygous variants in the SCLO4A1 gene. However, one in the ASXL3 gene was visible in the 
sequence data and therefore validated, and so remains as a viable candidate for causing the 
disease in this family (see figure 4-2). 
Figure 4-2: The chromatogram produced during validation of the ASXL3 variant by sequencing using the Sanger 
methodology. The variant is indicated by the arrow and is a heterozygous de novo variant. These chromatograms 




4.8 The remaining candidates 
4.8.1 ASXL3 
ASXL3 (Additional Sex Combs-Like 3) is found on chromosome 18 and is predicted to be a 
transcriptional regulator that epigenetically regulates some homeotic genes throughout 
development (Katoh, 2015). In the affected individual, the de novo variant is in the penultimate 
exon of the ASXL3 gene. Truncating variants in this exon have previously been described as 
causing Bainbridge-Ropers syndrome, one of which was only 60bp away (Bainbridge et al., 2013). 
Of the four variants described by Bainbridge et al. all caused early termination of the protein 
and therefore likely made the protein non-functional. Bainbridge-Ropers syndrome has a 
phenotype that could not be confused with Larsen syndrome (Robertson, personal 
communication), including psychomotor retardation, feeding problems and ulnar deviation of 
the hands. 
 The variant in this family is not truncating, but changes a polar amino acid (Serine) for a non-
polar one (Proline), possibly altering protein structure and therefore function. This could lead to 
the phenotype seen in the affected individual, in addition to explaining why the phenotype is 
different. As ASXL3 regulates transcription during development it is possible that altered 
function of the protein it produces could affect the expression of other genes. 
4.8.2 C18orf61 in conjunction with the intronic GNAL deletion 
C18orf61 is an uncharacterised open reading frame (ORF) of unknown function located on 




sequence that does not contain stop codons, more information is required to confirm the 
existence of a protein coding gene, but ORFs of this length are good indicators of possible 
protein-coding regions (Deonier, 2005). This means that variants within it could cause a change 
in phenotype. However, as there is no known function for C18orf61 and any there is a lack of 
information about possible regulatory effects of the intronic GNAL deletion, it is difficult to 
evaluate this variant, so although it remains a candidate it is of low priority and was not 
sequence validated. 
4.9 Discussion 
As the remaining candidates do not make a compelling case for causality in terms of their 
known function, it is not possible to confidently determine the exact causal variant in the family 
affected by Larsen syndrome. In order to accomplish this in the future, it would be useful to 
recruit additional atypical Larsen families with no causative variant in either the FLNB or 
B3GAT3 gene. Such families can then be used to find variants affecting genes in common, which 
provides support for any novel genes suggested to be causal. If this is not possible, as atypical 
Larsen families seem to be very rare, the causal variant could theoretically be determined 
through a variety of functional studies using one of a number of experimental systems, 
depending on the proposed function of the gene containing the variant suggested to be causal. 
For example, cell based assays of the variant could be performed, or the affected gene could be 
knocked out in zebrafish (Danio rerio) or mice (Mus musculus) if an ortholog exists. Performing 
such functional studies might allow predictions to be made about the phenotypic consequences 




It is possible that the real causal variant was accidentally removed during filtering in this 
investigation. Such an outcome could occur for a number of reasons, the most likely of which is 
that the causal variant was in a non-coding region and excluded due to a lack of the knowledge 
required to evaluate them. It could also have been removed due to having low base quality calls 
or issues during the annotation phase that caused it to be removed by the filters. It is also 
possible that the real causal variant could have been missed because it was not in the aligned 
data available. For example, the area the variant is in could be an area of the genome that 
doesn’t sequence well and is therefore not available in the aligned dataset, such as an area rich 
in GC bases. The causative variant could also have been missed because it was in an 
uncompleted part of the genome, as there are still sections of the human genome that are not 
fully known (Mostovoy et al., 2016). 
Additionally, the workflow that discovered and annotated structural variants could have missed 
a causal deletion. This is because it is less sensitive than the workflow that annotates SNVs and 
indels, and so requires stringent filtering to remove false positives, which can also remove real 
variants. There is also the possibility that the causal variant in this family is a different type of 
structural variant such as a duplication, which would not have been detected. In order to find 
such variants, it may be possible to use the GenomeStrIP CNV workflow (Handsaker et al., 2015) 
or other tools which can detect duplications and copy number variants as well as deletions. In 
order to find other structural rearrangements, such as inversions and translocations, other tools 
such as BreakDancer (Chen et al., 2009) can be used. 
Although no concrete answer was found as to the cause of the Larsen syndrome seen in this 




another atypical Larsen family is discovered, the ASXL3 gene and C18orf61 should be of 
particular interest and thoroughly searched. If another variant that could be causal is found in 
either ASXL3 or C18orf61 in another family, then the case for it causing the phenotype seen is 






5.1 The OPD1 family 
5.1.1 How did a misdiagnosis happen? 
The de novo variant in the CREBBP (CREB Binding Protein) gene was validated by sequencing 
using the Sanger methodology, and was predicted to truncate the protein produced by 
destroying a splice site. Many types of variant in the CREBBP gene are associated with various 
diseases including Rubinstein-Taybi syndrome (Petrij et al., 1995), non-Hodgkin lymphoma 
(Pasqualucci et al., 2011) and acute myelogenous leukaemia (Petrij et al., 1995). Rubinstein-
Taybi is most often caused by sporadic heterozygous de novo variants and has a phenotype 
similar to that of OPD1 with the addition of intellectual impairment (Rubinstein & Taybi, 1963). 
As variants similar to the one found in this family have been shown to cause Rubinstein-Taybi 
syndrome it was concluded that this individual has Rubinstein-Taybi syndrome instead of OPD-1, 
and that the initial diagnosis was mistaken. This is supported by the phenotype of the affected 
individual because the intellectual impairment shown is not typical of OPD1 but is common for 
Rubinstein-Taybi. 
There could be several reasons for the initial diagnosis being incorrect and remaining 
uncorrected for such a long time. Firstly, OPD1 and Rubinstein-Taybi have a lot of overlap in 
their phenotypes which can make them difficult to distinguish. For example, individuals affected 




addition to short stature. In addition to this, there are a huge number of rare genetic syndromes 
that often have complicated and subtle phenotypes that can vary between individuals.  
Secondly, the case presented in 1999, before the OPD spectrum of disorders was well defined. 
This meant that the clinicians diagnosing such individuals were less able to confidently diagnose 
someone as one of the OPD disorders. In addition to this, as the OPD disorders are quite rare it 
would not be unusual for the clinician in question to have never encountered someone affected 
by one of them before. These factors combined could have led to the clinician involved with this 
family incorrectly described the child as having OPD1. In addition to this, the diagnosis was 
accepted here using second hand information (a description of the affected individual with no 
images), which makes it more likely that the clinician will make a mistake during diagnosis. 
Finally, the techniques used here and the knowledge necessary to apply them were not yet 
developed at the time. The human genome project had not yet been completed and the 
function of many genes now known had not yet been discovered, which meant that clinical 
diagnosis was almost always carried out based on phenotype alone. This meant that if two rare 
syndromes had a similar phenotype, and had not been encountered by the clinician involved 
before, then it was possible for the diagnosis to be incorrect. If this occurred then the 
techniques used today were not able to be used to distinguish between the two possible 
syndromes, as at the time of this case it was very expensive to use genetic techniques to 
diagnose someone. Even if it could be afforded, genetic diagnosis was unlikely to be considered 




For these reasons it is not surprising that genetic syndromes are frequently misdiagnosed. 
However, a misdiagnosis can often be corrected by molecular analysis of the affected individual, 
as such an analysis can identify the exact variant likely to be causing the disease and therefore 
which gene is functioning abnormally to give the phenotype seen. If abnormal function of that 
gene is linked to another phenotypically similar syndrome that matches what is seen in the 
patient, as was the case with this family, then it is likely that the patient has that disease and 
the misdiagnosis can be corrected. The ability to correct such misdiagnoses is one of the reasons 
that molecular approaches such as whole genome analysis are valuable to clinicians. 
5.1.2 Rubinstein-Taybi Syndrome 
Rubinstein-Taybi is an autosomal dominant disease with a phenotype similar to that of OPD-1 
including broad thumbs, generalised bone dysplasia and short stature (Rubinstein & Taybi, 
1963). In addition to these traits, those affected by Rubinstein-Taybi normally have mental 
impairment, whereas those affected by OPD1 usually do not. The phenotype of the affected 
individual from the family involved in this investigation is in hindsight typical of Rubinstein-Taybi, 
strengthening the hypothesis that the CREBBP variant is causal and the individual was initially 
misdiagnosed. In addition to the traits listed, individuals affected by Rubinstein-Taybi have been 
found to be more susceptible to tumour formation, particularly neoplasms of the nervous 
system (Miller & Rubinstein, 1995). Individuals affected by Rubinstein-Taybi are also likely to 
have heart problems, as in previous literature cardiac abnormalities were found in 32.6% of 





Although this is a relatively trivial explanation for the case and it doesn’t illuminate any new 
biology as was hoped, this finding provides value to the family concerned in terms of a more 
confident diagnosis and a more accurate prognosis. As those affected by Rubinstein-Taybi are 
known to have a higher incidence of cardiac abnormalities and have a higher rate of tumour 
formation than those with a normal phenotype, correcting this diagnosis means that the family 
will be aware of these risks and better able to deal with them should they arise in the future. 
In addition to correcting the misdiagnosis, this finding also strengthens the hypothesis that 
OPD1 is exclusively caused by gain-of-function variants in the FLNA gene, as no variants known 
to cause OPD1 have yet been found in any other gene, even in this family where it initially 
seemed likely that that was the case. However, it remains possible that OPD1 can be caused by 
variants in another gene that simply haven’t been discovered yet.  
Finally, this case is a good example of the value of having access to high quality clinical 
information, such as images of the affected individual. Because the initial diagnosis was made 
based on only second-hand information with no images available, it was incorrect and remained 
uncorrected for nearly 20 years. While in this instance the prognosis for Rubinstein-Taybi was 
similar to that of OPD1, at other times this may not be the case, and an incorrect diagnosis 
could lead to long term harm for the individual. For example, many of the disorders similar to 
OPD1 share some traits, but have different long-term outcomes, so high quality information is 




individual showing the abnormal traits is very useful in the event that an in-person examination 





5.2 The Larsen Family 
5.2.1 The remaining candidates 
The remaining candidate variants are in genes that are not known to have a function that could 
cause Larsen syndrome if disrupted. Because of this, it is not possible to definitively state that 
either of them is the exact cause of this individual’s Larsen syndrome. However, it is possible 
that one of them is causal. This can be confirmed in the future if another family with 
unexplained Larsen is discovered, as the ASXL3 gene and C18orf61 can be investigated to find 
any variants that could be causal.  
 ASXL3 
One of the remaining candidates is a de novo variant in the ASXL3 gene, which is known to cause 
Bainbridge-Ropers syndrome if damaged. ASXL3 produces an epigenetic scaffold protein and 
has a loss of function tolerance score of 1.0 in ExAC, which means that it is highly intolerant of 
single base variants that could cause loss of function, to such an extent that the gene is 
haploinsufficient (Lek et al., 2016). In addition to this, the candidate de novo is predicted to 
change an amino acid in the protein produced by SnpEff 4.2, and therefore has the potential to 
alter function. The candidate variant has also not been found previously. These factors make it a 
reasonable candidate, but not one strong enough that it can be deemed causal without further 
supporting evidence.  
5.2.1.1.1 Gene function and known associated diseases 
ASXL3 produces a protein that is an epigenetic scaffold, involved in the regulation of nuclear 




2015). It is part of a gene family that is critical to development, as components of the signal 
transduction pathway from members of the ASXL gene family affect the pathways of other 
epigenetic regulators during physiological, pathological and developmental processes (Katoh, 
2015). Dysregulation of epigenetic processes such as this can cause a variety of diseases in 
humans because epigenetic regulators are critical for normal cellular differentiation (Ordovas & 
Smith, 2010). 
 Because of this, variants that affect the function of ASXL genes can cause a variety of diseases 
in humans, including Bohring-Opitz syndrome (ASXL1) and many cancers such as breast, liver 
and bladder cancer (Katoh, 2015). Truncating variants in ASXL3 in particular have been 
implicated in autism (De Rubeis et al., 2014), Bainbridge-Ropers syndrome (Bainbridge et al., 
2013), and melanoma (Berger et al., 2012). The variants previously described to cause 
Bainbridge-Ropers syndrome are located throughout the gene with the exception of the 
beginning. As the last two exons of ASXL3 are much larger than the others, most of these 
variants are in the same exon as the variant found in this family, exon 11 (Kuechler et al., 2017), 
one of which was only 60bp away (Bainbridge et al., 2013). However, Bainbridge-Ropers 
syndrome has a phenotype that could not be confused with Larsen syndrome, including 
psychomotor retardation, feeding problems and ulnar deviation of the hands (Robertson, 
personal communication). 
5.2.1.1.2 The candidate variant 
The exon containing the candidate variant in this family is the second to last one in the ASXL3 




produced, either making it non-functional or possibly causing a gain of function, leading to 
Bainbridge-Ropers syndrome. The candidate variant in this family is not truncating and 
therefore is less likely to cause Bainbridge-Ropers syndrome as it is a different kind of variant to 
those that classically cause the disease. However, it is possible that it could cause a different 
phenotype such as Larsen’s syndrome, or be completely benign. The missense variant seen in 
this family, particularly because it is predicted to affect protein structure, could cause a gain of 
function or non-function of the protein produced. Specifically, the variant is predicted to change 
a Serine, a polar amino acid, to a non-polar one, Proline.  
5.2.1.1.3 Possible effects of the variant 
The variant in this family changes a polar amino acid (Serine) for a non-polar one (Proline), 
possibly disrupting protein structure and therefore function. This could affect the function of 
the protein as usually polar amino acids are located on the outside of the protein to allow for 
interaction with other molecules while non-polar ones are in the interior (Alberts et al., 2014). 
Changing the charge of an amino acid can therefore change the structure of the protein and 
how it interacts, which could possibly lead to gain of function and the phenotype seen in the 
affected individual. As ASXL3 epigenetically regulates transcription during development, either 
non-function of the protein it produces or a change in its function could affect the expression of 
other genes. In addition to this, the fact that the variant is not truncating but still could affect 
protein function would explain why the phenotype is different when compared to other 




5.2.1.1.4 What does this mean for Filamin B? 
In the event that the ASXL3 de novo candidate variant is found to be causal through future work, 
it might suggest that filamin B interacts with ASXL3 in some way. For example, it was found to 
be causal it may be suggested that transcription of the FLNB gene is normally epigenetically 
regulated by ASXL3, and that FLNB is sensitive to altered function of that protein. This would 
mean that either too much or too little filamin B was produced during development due to loss 
of normal transcriptional regulation of FLNB, which could then lead to the disorder seen in this 
family.  
If this was the case it would enhance our understanding of filamin B and how it operates during 
development, including what molecules or receptors with which it is likely to interact. This 
would in turn lead to a better understanding of the cellular processes involved, especially for 
the development of the skeleton during development.  
 C18orf61 in conjunction with the intronic GNAL deletion 
The second candidate that remains is a heterozygous single base variant in C18orf61, an open 
reading frame (ORF), in conjunction with a heterozygous intronic deletion in the GNAL gene, 
roughly 500,000bp away. Both the function of C18orf61 and how it could be regulated by the 
GNAL deletion are unknown, and so it is very difficult to assess the possible impact this 
candidate could have. Although the two variants in combination remain a candidate for causing 
the disease in this family, due to the lack of information available about how they could cause 




5.2.2 What does this mean for the family and others affected by Larsen 
Syndrome? 
Even though the exact causal variant in this family could not be determined as it was for the 
OPD1 family, this study still provides some value as two candidate variants remained, one in the 
ASXL3 gene and the other in C18orf61 in combination with an intronic deletion in the GNAL 
gene between bases 11,730,592 and 11,732,061 on chromosome 18. However, neither of them 
is a compelling candidate. The ASXL3 gene is not known to have any function that when 
disrupted could lead to the phenotype seen, and C18orf61 is both of unknown function and it is 
not known how the intronic GNAL deletion could affect its regulation. It is possible that the true 
causal variant was missed for any of a number of reasons. For example, it is possible that the 
disease seen in this individual is not caused by genetic factors but environmental ones, or the 
causal variant could be in a region not adequately covered for technical reasons such as 
repetitive regions and regions high in GC bases. It is also possible that the causal variant lies in a 
non-coding region, which could mean that although the sequence data was available it was not 
adequately screened due to the large number of variants present and the current lack of 
knowledge about the functional effects of non-coding variants. In addition to these reasons, it is 
possible that the causal variant could have been missed in this analysis because it is in a region 
of structural polymorphism that is not adequately described by the reference sequence used 
and so was not visible, or because the cause of the disease is a rare structural variant not 




For the reasons above, the remaining candidates are not compelling enough to justify 
undertaking functional investigation of them. However, in the event of the discovery of another 
family affected by this rare type of Larsen syndrome it would be possible to strengthen the case 
for either variant being causal if the gene in question was found to harbour a significant variant 
in the second family. In this event, there is the possibility of further functional work being 
undertaken to determine if either variant is causal, including cell based assays of the candidate 
variant or knockdowns of the affected gene in zebrafish (Danio rerio) to observe the resulting 
phenotypes. In the event that the causal variant is identified through such means it would be 
useful for physicians, who would be better able to diagnose the disease through genetic 
techniques. This in turn can provide value to the affected family, as it can lead to better 
management strategies and an improved diagnosis.  
5.2.3 How could we determine the causal variant in the Larsen family? 
Although neither of the remaining candidates are compelling enough to justify functional 
assessment at this point, in the future evidence obtained from another individual or family may 
strengthen the case for one variant to be causal, to the point that functional testing of the 
variant will be necessary. If this occurs there are several options that can be used to determine 
if the candidate thought to be causal is, including cellular assays based on the function of the 
proteins thought to be affected and knockdowns in animal models. 
 Cellular assays 
One way a strong candidate can be assessed functionally is to cause the suggested causal 




expected phenotype.  For example, as the product of the ASXL3 gene is involved in the 
epigenetic regulation of many genes during development, it would be necessary to choose a cell 
line that expresses the ASXL3 gene as well as one or more of the genes it is known to regulate, 
in a suitable environment for normal regulatory function. If this was achieved it would then be 
possible to determine what effect changing the ASXL3 gene by causing the candidate variant 
would have on that pathway and therefore whether the ASXL3 variant could be causal.  
If the cellular assay showed phenotypic changes in the cell line that could be attributed to the 
variant introduced, it would support the hypothesis that that variant was causal, and further 
functional work could be undertaken using an animal model to further investigate the likely 
effects of the variant in question. 
 Knockdowns in Zebrafish or knockout mice 
Following a successful assessment of the candidate variant using cellular assays, or as an 
alternative, it would be possible to further strengthen the argument for that variant being 
causal by recreating the candidate variant in an animal model and observing the resultant 
phenotypic effects in an attempt to recapitulate the relevant parts of the disease phenotype. 
There are several animal models that could be used, but the most common ones are zebrafish 
and mice. As zebrafish are cheaper and easier to use than mice, they are more often used to 
determine if strong candidate variants are in fact causal. However, as mice are more closely 
related to humans it is more likely that an ortholog will exist in mice than in zebrafish. For 
example, there is no known ortholog for the ASXL3 gene in zebrafish but there is in mice. It is 




lethal. For these reasons, if functional work were ever to be performed using an animal model, 
it may be necessary to use mice to investigate the variant in the ASXL3 gene, but zebrafish to 
examine other variants found by further analysis due to the difference in cost and ease of 
utilisation. 
In addition to the above issues, as these species are biologically different to humans the 
phenotype produced may not be the same as it would be in humans, which can make it difficult 
to properly assess the effect of a candidate variant. For Larsen’s syndrome, however, if the 
disease phenotype was replicated in either mice or zebrafish, it could be relatively easy to 
assess as it consists of mainly bone malformations and deafness, both of which could be 
assessed in either species even though the exact changes may not be identical to the phenotype 
in humans. For example, whether the variant caused deafness in Zebrafish or not could be 
assessed through playing a loud noise and observing the response via a camera. If the Zebrafish 
did not exhibit the classic startle response then it is likely that their hearing has been impaired, 
possibly by the introduced variant (Yang et al., 2017).  Such functional tests are not currently 
recommended however, as the support for the remaining candidates is not strong enough to 
justify them. 
 Finding another family 
The most straightforward and likely way the correct causal variant in the Larsen family could be 
determined is using another family with the same type of unexplained Larsen syndrome. Having 
a second family containing an affected individual means that their genomic sequence can be 




greatly enhancing the power of the methods used here and increasing support for implicated 
genes if they are found to contain multiple independent variants. However, although this way 
would effectively increase support for a suggested causal gene, it relies on finding another 
family with the same type of Larsen syndrome as the one used here. Since the current family is 
the only known case of Larsen syndrome not caused by a variant in either FLNB or B3GAT3, it 
can be considered extremely rare, and therefore it is not likely that a second family will be 
found in the near future. 
5.3 Whole Genome Sequencing 
5.3.1 Advantages 
There are several advantages to using whole genome sequence to locate causal variants 
compared to exome sequence, namely that whole genome sequence gives higher quality 
sequence of the exome and provides a greater potential for researchers to find structural 
variants. One possible advantage of using whole genome sequence is that when using recently 
developed methods to obtain whole genome sequence PCR-amplification of a library of 
sequences is not necessary, and there is no capturing or hybridization step (Belkadi et al., 2015). 
This means that the areas of the genome missed when an exome is produced are more likely to 
be included in the resulting sequence, as well as reducing the bias towards certain areas of the 
genome and giving more uniform depth of coverage across the genome in general and 
therefore more reliable base calls. However, in most cases, including this analysis, PCR is still 




As well as giving more complete coverage of the genome and more reliable base calls than 
exome data, using whole genome sequence provides greater potential for the discovery of 
some structural variants, which is more difficult when using exome sequence because there is 
no simple way to search or filter for them as the available methods are both less accurate and 
less sensitive. 
In addition to these advantages, genome data is becoming easier to utilise all the time. 
Currently there are many excellent tools available for analysis, especially those available in the 
Genome Analysis Toolkit (GATK) which includes many of the tools used here. Having these tools 
available means that if genome sequence data is available, it can be effectively searched for 
causative variants with relative ease. This means that although in the past searching an entire 
genome for a candidate might have been incredibly difficult, it can now be done relatively easily. 
Furthermore, the tools available are improved and new tools are created all the time, which 
means that in the future using whole genome sequence will become even easier. 
A further possible advantage of using whole genome sequence to search for causal variants is 
that it makes it possible to locate causal non-coding variants. Although exome sequence will 
contain information on splice site variants, as well as roughly the first 100bp of each intron, it 
does not contain information about the remaining intronic regions, which can lead to the causal 
variant not being found. However, the number of non-coding variants is extremely large when 
using whole genome sequence and there is currently little information available that can be 
used to effectively filter and assess them. This means that in most cases, the majority of intronic 
variants are filtered out when using whole genome sequence, so while having sequence data on 




this difficulty, it is expected that in the future as there is further development of databases 
describing functional elements in non-coding regions, such as the Encyclopaedia of DNA 
Elements (ENCODE), it will be possible to better examine non-coding variants, providing a 
further advantage to using whole genome sequence. 
5.3.2 Limitations 
 Structural variants 
5.3.2.1.1 Finding structural variants is difficult 
Despite the increased availability and ease of utilisation of genomic data there are still some 
issues that indicate a need for improvement. Firstly, even though the tools involved are useful, 
it is still difficult to reliably find structural variants. Variants that are insertions or duplications 
are particularly hard to find, which means that if the causal variant is one of these, it can be 
easily missed. This can lead to other candidates being investigated, which leads to a lot of 
wasted time and resources. However, as stated above, new and improved tools are constantly 
being developed that make it easier to find such variants. Additionally, this difficulty with 
structural variants is not unique to whole genome sequence but is shared by other methods, 
particularly exome data. 
5.3.2.1.2 Population size when looking at structural variants 
When looking for structural variants, the large online databases of exome and genome data 
cannot be used to directly annotate the variants discovered, as the start and end positions of 
the structural variations they contain are approximate. This means that the structural variants 




ambiguity makes it necessary to use individuals processed together throughout the genotyping 
phase of the SV workflow as the population. While this enables a certain level of confidence in 
calculating the frequency of the variants involved, it is not as useful as using the databases due 
to the smaller number of individuals involved making it possible that a relatively common 
variant simply is not represented. 
5.3.2.1.3 GenomeStrIP CNV Workflow 
The workflow that can be used to locate further structural variants that could be causal is called 
GenomeStrIP CNV and utilises tools from the GATK (Handsaker et al., 2015). This tool builds on 
the SV version of this workflow by adding functionality that enables the location of insertions 
and duplications to be determined and annotated in addition to those of deletions. This new 
workflow will make it far easier to find structural variants in genomic data, but does not work 
with exome data. The CNV workflow scans overlapping regions of the genome, analysing read 
depth to look for evidence of structural variants, as variants such as insertions, deletions and 
duplications will alter the read depth, such as by decreasing it by roughly half in the case of a 
heterozygous deletion. However, as it is highly complex and difficult to implement, it was not 
used for this analysis. In addition, there are many other tools available that are designed to 
identify structural variants form sequence data, but due to time and difficulty constraints not all 
of them have been investigated or implemented. 
 Such massive quantities of data are difficult to properly investigate 
Another issue that can arise when using whole genomes is that the amount of data involved is 




genome sequence, the dataset usually contains a number of variants that greatly exceeds what 
can reasonably be assessed manually. Such amounts of data make it necessary to filter out 
many of the suggested variants so that it is possible to examine the rest at all. Although this 
filtering is helpful, as it removes most of the false positive results and leaves only the candidates 
that are likely to be affecting gene function, it is possible to accidentally filter out the causal 
variant in the process. Again, however, this issue does not only affect whole genome data but 
also affects whole exome data, although it is much more pronounced when using genome data. 
To combat this issue, it is necessary to use conservative filters that retain more of the suggested 
variants, to remove most of the false positives but as few of the real ones as possible. 
 The reference sequence is an approximation 
Whole genome sequence is obtained by aligning fragments of sequence data to a reference 
sequence. However, it is normal for there to be multiple alleles at many loci in the human 
genome, and such alternative alleles are often not represented in the reference sequence. This 
means that it is possible for something to be annotated as a possibly causative variant when in 
fact it is simply a normal alternative allele. Because of this, it is necessary to ensure that any 
candidate variants are not simply alleles different to those of the reference sequence by 
checking the frequency of the supposed variant against a large population. 
 Many false positives are present in the dataset 
Finally, it is necessary to note that the sequence data itself contains many false positive variants, 
which are variants that are annotated as not matching the reference sequence but often do on 




when using genome data and if they are retained after filtering can cause incorrect conclusions 
to be drawn, so it is necessary to take extra steps to ensure the variants exist. This can include 
using the Sanger methodology to sequence across the variant’s location to prove that it is in fact 
there.  
5.3.3 Is secondary sequencing to detect false positive variants still 
necessary? 
Until recently, it was thought necessary to use a secondary sequencing methodology, such as 
the Sanger methodology, to strengthen the case that the variants thought to be causing disease 
were not false positives. This was because high throughput sequencing technology early on 
often made errors in base calls, either due to low fluorophore concentration or other associated 
issues, which led to a relatively high number of false positive variants being defined as causing 
disease (Bell et al., 2011). However, as these sequencing technologies have developed they 
have become more reliable, so using a secondary sequencing methodology to confirm the 
presence of variants found by the initial method is becoming less common. 
Despite this, in this study, several variants passed the filters applied and so were considered 
candidates, but when sequencing using the Sanger methodology was used to attempt to verify 
their presence the resulting sequence was found to match the reference sequence. This 
suggested that those variants were incorrectly called during initial sequencing, and that the real 
base matched the reference sequence. If the secondary confirmation sequencing step was not 
carried out, it is possible that these variants would still be candidates, which would be incorrect. 




accurate base calls such as the Sanger methodology or PCR followed by high depth Illumina 
sequencing is still necessary even though current sequencing methods generally lead to 
accurate base calls. This is because in the event that a base is initially called incorrectly, and 
because of that an incorrect variant is ascribed causality, a great deal of time and resources 
could be wasted trying to understand how the gene involved interacts with other factors to 
produce the phenotype seen.  
However, even though a second sequencing methodology returning the same base at a given 
position as the first method strengthens the base call, it is also possible that the second method 
is also incorrect. For example, the Sanger methodology has low sensitivity when multiple alleles 
are present, such as in the case of mosaicism, which can lead to incorrectly classifying candidate 
variants as false positives. In addition, PCR followed by high depth Illumina sequencing is not 
very economical when confirming the accuracy of only one possible variant, although this can 
be resolved by running multiple fragments down the same lane to confirm multiple variants at 
the same time.  
 Will it remain necessary to use secondary sequencing to detect false positive 
variants? 
Although it is still necessary to use a secondary sequencing methodology to confirm the 
presence of many candidate variants, the advent of several new sequencing technologies that 
give highly accurate base calls across incredibly long reads are likely to both negate the need for 
a reference sequence and provide an alternative to short read sequencing methodologies such 




Nanopore sequencing, provide incredibly long reads of 10,000bp on average from single 
molecules (Vembar et al., 2016). Producing such long reads greatly improves the mappability, or 
uniqueness, of reads within a genome (Sims, Sudbery, Ilott, Heger, & Ponting, 2014), which 
makes it possible to unambiguously align the sequences and therefore assemble genomes 
without the use of a reference genome, i.e. de novo. In addition to this, long reads can span 
repetitive elements and complex regions without introducing errors that lead to false positive 
results. Finally, using long reads to assemble a genome enables the determination of structural 
variants, as at such lengths it is possible to sequence across most of them (Merker et al., 2016). 
In addition, although the rate at which these methods make incorrect base calls is relatively high, 
the base calling errors are random rather than systematic, which means that a relatively low 
read depth is capable of minimising the number of incorrect calls in the final sequence data 
(Roberts, Carneiro, & Schatz, 2013). This in turn greatly reduces the number of false positive 
variants produced, which means that it is generally unnecessary to confirm the existence of 
candidate variants through further sequencing methods. 
However, despite these advantages, it is often not practical to use this methodology because it 
is very expensive as well as being incredibly computationally demanding. As such, it is not yet 
used routinely on the scale of whole human genomes and so was not appropriate to use for this 
analysis. In the future, it is expected that utilising such sequencing technologies will become less 
expensive and more accessible, and therefore an appropriate choice for the determination of 




5.4 Future analysis 
While no further work is recommended at present, it is possible that in the future a second 
family affected by unexplained Larsen syndrome will be discovered. In this event, the ASXL3 
gene and C18orf61 should be of particular interest, as if variants that could be causal are found 
in these genes in a second family the case for it causing the Larsen phenotype seen is made 
much stronger, to the point that functional studies would be recommended to determine if the 
gene in question was truly causal. In addition, it may be worth revisiting the Larsen family case 
in several years, once better tools for locating variants that are currently hard to detect, such as 
structural variants, are available, as a causal variant that was missed in this analysis could 
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7  Appendices 
7.1  Appendix One: Depth of coverage for Genomic sequence data 
Depth of coverage statistics for each individual were obtained from the bam files using the 
GATK DepthOfCoverage tool, shown in the table below.  
sample_id mean %_bases_above_10 %_bases_above_20 %_bases_above_30 
182 38.23 98.9 97.9 84.2 
183 35.59 98.9 97.4 75.4 
184 38.07 99.6 95.5 82.2 
3060 45.95 99 98.3 95.1 
3061 33.68 98.9 96.5 66.3 
3062 35.39 99.5 94.3 73.5 
 
A description of the SNPs and Indels was obtained from variant call file using the Picard 




7.2  Appendix Two: A low quality FLNA variant as seen in IGV 
 A screenshot of IGV showing the low quality of the de novo variant found in the FLNA gene in 
individual 182 of the OPD1 family. Its location is indicated by the arrow. The copy number is 
much lower than the average and it is situated at the end of many reads. Coloured reads are 
discordant pairs of reads where one read of the pair has mapped to this location and the other 
has mapped to a different chromosome. This suggests that there were issues with aligning the 
pairs correctly and that the variant seen here is unlikely to be real. In addition, the extended 
stretch of A bases suggests that this region is subject to polymerase stutter during library 





7.3  Appendix Three:  De novo variants in the OPD1 family 
A list of variants found through the de novo model in the family affected by OPD1 that remained 
after filtering for any locations where both the mother and father matched the reference 
sequence but the child did not, where the variant was likely to have an impact on gene function. 
Any gene with a loss of function tolerance below 0.4 as calculated by ExAC (URL 
http://exac.broadinstitute.org/) was excluded where the variant was a single base change as 
unlikely to be causing disease. NA means that there was no information available for loss of 
function tolerance in ExAC for that gene. In addition, any variant inside a mono or di-nucleotide 
repeat was excluded as they were likely the result of PCR slippage or an error of alignment. 
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7.4  Appendix Four: De novo variants in the Larsen family 
A list of variants found through the de novo model in the family affected by Larsen syndrome 
that remained after filtering to find any locations where the mother and father matched the 
reference sequence but the child did not, where the variant was likely to have an impact on 
gene function. Any gene with a loss of function tolerance below 0.4 as calculated by ExAC (URL 
http://exac.broadinstitute.org/) was excluded where the variant was a single base change as 
unlikely to be causing disease (an NA means that there was no information available about LoF 
in ExAC for that gene).  Also excluded were variants in hypothetical transcripts, such as those in 
GOLGA6L19, as there is no direct evidence that they exist. In addition, any variant inside a mono 
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7.5 Appendix Five: Recessive candidates from the Larsen family 
A list of the recessive candidates, both homozygous and compound heterozygous, in the family 
affected by Larsen syndrome that remained after filtering. In order to find homozygous 
candidates, the data was filtered for locations where the affected individual was homozygous 
variant and both the mother and the father were heterozygous, where the genotype quality was 
greater than ten, the variant was present at a frequency below 0.001 in both ExAC and 1000 
genomes, and the variant was predicted to have either a high or moderate impact on the 
protein produced.   
In order to find compound heterozygous candidates, the data was first filtered for locations 
where the child and father were heterozygous but the mother was homozygous reference. Then 
locations where the child and mother were heterozygous but the father was homozygous 
reference were filtered for. Following this a list was made of all the genes where the child had 
inherited at least one variant from the mother, as well as at least one variant from the father. 
The candidates were then further filtered to include only variants present at a frequency of less 
than 0.001 in both ExAC and 1000 Genomes, that were not in VQSRTrancheSNP99.90to100.00, 
and had a genotype quality greater than 10. 
Any gene with high-confidence LOF homozygote variants present in ExAC (URL 
http://exac.broadinstitute.org/) was excluded where the variant was a single base change as 
likely to be tolerant of such variants without causing disease. Also excluded were any variants in 
pseudogenes (SPATA31E3P) and those in T-Cell receptor genes (TRBV10-1) as they are normally 




1988). In addition, any variant inside a mono or di-nucleotide repeat was excluded as they were 
likely the result of either PCR slippage or an error during alignment. Variants that fell into 
VQSRTrancheSNP99.90to100.00 were also excluded. 
As there were too many candidate variants remaining to reasonably analyse through secondary 
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